drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00514 | DB01320 | 506 | 651 | [
"DDInter527",
"DDInter783"
] | Dextromethorphan | Fosphenytoin | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Moderate | 1 | [
[
[
506,
24,
651
]
],
[
[
506,
63,
362
],
[
362,
1,
651
]
],
[
[
506,
6,
6017
],
[
6017,
45,
651
]
],
[
[
506,
21,
28691
],
[
28691,
60,
651
]
],
[
[
506,
63,
999
],
[
999,
24,
651
]
],
[
[
506,
24,
832
],
[
832,
24,
651
]
],
[
[
506,
24,
849
],
[
849,
63,
651
]
],
[
[
506,
24,
760
],
[
760,
64,
651
]
],
[
[
506,
24,
1419
],
[
1419,
25,
651
]
],
[
[
506,
63,
752
],
[
752,
25,
651
]
]
] | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosphenytoin"
]
]
] | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Dextromethorphan (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fosphenytoin (Compound)
Dextromethorphan (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Fosphenytoin (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Fosphenytoin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Fosphenytoin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may lead to a major life threatening interaction when taken with Fosphenytoin |
DB00675 | DB01087 | 888 | 1,520 | [
"DDInter1744",
"DDInter1520"
] | Tamoxifen | Primaquine | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977. | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404) | Moderate | 1 | [
[
[
888,
24,
1520
]
],
[
[
888,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
888,
6,
12523
],
[
12523,
45,
1520
]
],
[
[
888,
18,
8800
],
[
8800,
57,
1520
]
],
[
[
888,
21,
28722
],
[
28722,
60,
1520
]
],
[
[
888,
23,
112
],
[
112,
23,
1520
]
],
[
[
888,
24,
479
],
[
479,
23,
1520
]
],
[
[
888,
74,
508
],
[
508,
24,
1520
]
],
[
[
888,
63,
618
],
[
618,
24,
1520
]
],
[
[
888,
24,
1342
],
[
1342,
63,
1520
]
]
] | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Primaquine"
]
],
[
[
"Tamoxifen",
"{u} (Compound) downregulates {v} (Gene)",
"RBM34"
],
[
"RBM34",
"{u} (Gene) is downregulated by {v} (Compound)",
"Primaquine"
]
],
[
[
"Tamoxifen",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Primaquine"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primaquine"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primaquine"
]
],
[
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
]
] | Tamoxifen may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Tamoxifen (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Primaquine (Compound)
Tamoxifen (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Primaquine (Compound)
Tamoxifen (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Primaquine (Compound)
Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Primaquine
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Primaquine
Tamoxifen (Compound) resembles Promazine (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine |
DB00277 | DB00280 | 1,031 | 494 | [
"DDInter1791",
"DDInter575"
] | Theophylline | Disopyramide | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Moderate | 1 | [
[
[
1031,
24,
494
]
],
[
[
1031,
6,
8374
],
[
8374,
45,
494
]
],
[
[
1031,
21,
28658
],
[
28658,
60,
494
]
],
[
[
1031,
24,
752
],
[
752,
62,
494
]
],
[
[
1031,
24,
1486
],
[
1486,
63,
494
]
],
[
[
1031,
63,
1184
],
[
1184,
24,
494
]
],
[
[
1031,
25,
497
],
[
497,
63,
494
]
],
[
[
1031,
24,
609
],
[
609,
64,
494
]
],
[
[
1031,
63,
702
],
[
702,
25,
494
]
],
[
[
1031,
6,
8374
],
[
8374,
45,
675
],
[
675,
40,
494
]
]
] | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Disopyramide"
]
],
[
[
"Theophylline",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Disopyramide"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Disopyramide"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Disopyramide"
]
]
] | Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Disopyramide (Compound)
Theophylline (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Disopyramide (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Disopyramide
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide
Theophylline may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Disopyramide
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Disopyramide
Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dextropropoxyphene (Compound) and Dextropropoxyphene (Compound) resembles Disopyramide (Compound) |
DB05239 | DB11003 | 866 | 748 | [
"DDInter425",
"DDInter100"
] | Cobimetinib | Anthrax vaccine | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
866,
24,
748
]
],
[
[
866,
63,
322
],
[
322,
24,
748
]
],
[
[
866,
25,
676
],
[
676,
63,
748
]
],
[
[
866,
24,
1683
],
[
1683,
24,
748
]
],
[
[
866,
24,
1619
],
[
1619,
63,
748
]
],
[
[
866,
64,
1057
],
[
1057,
24,
748
]
],
[
[
866,
25,
1011
],
[
1011,
24,
748
]
],
[
[
866,
63,
322
],
[
322,
63,
168
],
[
168,
24,
748
]
],
[
[
866,
25,
676
],
[
676,
64,
322
],
[
322,
24,
748
]
],
[
[
866,
24,
1683
],
[
1683,
63,
322
],
[
322,
24,
748
]
]
] | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
]
] | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Cobimetinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Cobimetinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Cobimetinib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Cobimetinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
DB00361 | DB11828 | 134 | 1,406 | [
"DDInter1939",
"DDInter1281"
] | Vinorelbine | Neratinib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug. | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
134,
24,
1406
]
],
[
[
134,
25,
1510
],
[
1510,
24,
1406
]
],
[
[
134,
24,
985
],
[
985,
24,
1406
]
],
[
[
134,
24,
1619
],
[
1619,
63,
1406
]
],
[
[
134,
23,
255
],
[
255,
63,
1406
]
],
[
[
134,
24,
1554
],
[
1554,
25,
1406
]
],
[
[
134,
24,
283
],
[
283,
64,
1406
]
],
[
[
134,
25,
609
],
[
609,
25,
1406
]
],
[
[
134,
23,
307
],
[
307,
25,
1406
]
],
[
[
134,
63,
529
],
[
529,
25,
1406
]
]
] | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
],
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
]
] | Vinorelbine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Colchicine and Colchicine may lead to a major life threatening interaction when taken with Neratinib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Neratinib
Vinorelbine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Neratinib
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may lead to a major life threatening interaction when taken with Neratinib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may lead to a major life threatening interaction when taken with Neratinib |
DB00370 | DB12130 | 1,251 | 1,017 | [
"DDInter1230",
"DDInter1094"
] | Mirtazapine | Lorlatinib | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
1251,
24,
1017
]
],
[
[
1251,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1251,
24,
126
],
[
126,
24,
1017
]
],
[
[
1251,
25,
11
],
[
11,
24,
1017
]
],
[
[
1251,
24,
971
],
[
971,
63,
1017
]
],
[
[
1251,
63,
1010
],
[
1010,
24,
1017
]
],
[
[
1251,
25,
877
],
[
877,
63,
1017
]
],
[
[
1251,
24,
1220
],
[
1220,
25,
1017
]
],
[
[
1251,
24,
283
],
[
283,
64,
1017
]
],
[
[
1251,
63,
1101
],
[
1101,
62,
608
],
[
608,
23,
1017
]
]
] | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
]
] | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirtazapine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirtazapine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Lorlatinib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib |
DB00975 | DB06822 | 1,317 | 802 | [
"DDInter573",
"DDInter1812"
] | Dipyridamole | Tinzaparin | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Major | 2 | [
[
[
1317,
25,
802
]
],
[
[
1317,
23,
944
],
[
944,
62,
802
]
],
[
[
1317,
24,
222
],
[
222,
24,
802
]
],
[
[
1317,
63,
383
],
[
383,
24,
802
]
],
[
[
1317,
24,
1427
],
[
1427,
63,
802
]
],
[
[
1317,
64,
1432
],
[
1432,
25,
802
]
],
[
[
1317,
25,
1409
],
[
1409,
25,
802
]
],
[
[
1317,
25,
405
],
[
405,
64,
802
]
],
[
[
1317,
63,
1338
],
[
1338,
25,
802
]
],
[
[
1317,
24,
885
],
[
885,
25,
802
]
]
] | [
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Dipyridamole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tinzaparin"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
],
[
"Meclofenamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
]
] | Dipyridamole may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Dipyridamole may lead to a major life threatening interaction when taken with Abciximab and Abciximab may lead to a major life threatening interaction when taken with Tinzaparin
Dipyridamole may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Tinzaparin
Dipyridamole may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Tinzaparin
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may lead to a major life threatening interaction when taken with Tinzaparin
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Tinzaparin |
DB00851 | DB00970 | 611 | 0 | [
"DDInter463",
"DDInter466"
] | Dacarbazine | Dactinomycin | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) | Moderate | 1 | [
[
[
611,
24,
0
]
],
[
[
611,
5,
11635
],
[
11635,
44,
0
]
],
[
[
611,
7,
7669
],
[
7669,
57,
0
]
],
[
[
611,
23,
246
],
[
246,
62,
0
]
],
[
[
611,
62,
1299
],
[
1299,
23,
0
]
],
[
[
611,
24,
259
],
[
259,
63,
0
]
],
[
[
611,
63,
1184
],
[
1184,
24,
0
]
],
[
[
611,
64,
1648
],
[
1648,
24,
0
]
],
[
[
611,
25,
1377
],
[
1377,
64,
0
]
],
[
[
611,
64,
1057
],
[
1057,
25,
0
]
]
] | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Dacarbazine",
"{u} (Compound) treats {v} (Disease)",
"muscle cancer"
],
[
"muscle cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Dactinomycin"
]
],
[
[
"Dacarbazine",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dactinomycin"
]
],
[
[
"Dacarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dactinomycin"
]
],
[
[
"Dacarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dactinomycin"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dactinomycin"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dactinomycin"
]
]
] | Dacarbazine (Compound) treats muscle cancer (Disease) and muscle cancer (Disease) is treated by Dactinomycin (Compound)
Dacarbazine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is downregulated by Dactinomycin (Compound)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Dactinomycin
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Dactinomycin
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Dacarbazine may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Dacarbazine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Dactinomycin
Dacarbazine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Dactinomycin |
DB00783 | DB01261 | 1,438 | 170 | [
"DDInter679",
"DDInter1679"
] | Estradiol | Sitagliptin | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vaginal rings, transdermal patches, sprays, gels, and creams.[L11485,L11488,L11491, L11494,L11497,L11500,L11503] When used for oral or IM administration, estradiol is commonly synthesized as a pro-drug ester (such as,,,, and ). Because it has a low oral bioavailability on its own, estradiol is commonly formulated with an ester side-chain. (EE) is a synthetic form of estradiol commonly used as the estrogenic component of most combination oral contraceptive pills (OCPs). Ethinyl estradiol is different from estradiol due to its higher | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006. | Moderate | 1 | [
[
[
1438,
24,
170
]
],
[
[
1438,
6,
3486
],
[
3486,
45,
170
]
],
[
[
1438,
18,
1948
],
[
1948,
57,
170
]
],
[
[
1438,
21,
28850
],
[
28850,
60,
170
]
],
[
[
1438,
24,
52
],
[
52,
62,
170
]
],
[
[
1438,
24,
708
],
[
708,
63,
170
]
],
[
[
1438,
63,
1179
],
[
1179,
24,
170
]
],
[
[
1438,
24,
629
],
[
629,
24,
170
]
],
[
[
1438,
1,
890
],
[
890,
63,
170
]
],
[
[
1438,
1,
559
],
[
559,
24,
170
]
]
] | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Estradiol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Estradiol",
"{u} (Compound) downregulates {v} (Gene)",
"IFNAR1"
],
[
"IFNAR1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Estradiol",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sitagliptin"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Estradiol",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Estradiol",
"{u} (Compound) resembles {v} (Compound)",
"Estrone"
],
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
]
] | Estradiol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sitagliptin (Compound)
Estradiol (Compound) downregulates IFNAR1 (Gene) and IFNAR1 (Gene) is downregulated by Sitagliptin (Compound)
Estradiol (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Estradiol (Compound) resembles Mestranol (Compound) and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Estradiol (Compound) resembles Estrone (Compound) and Estrone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin |
DB00238 | DB08899 | 188 | 129 | [
"DDInter1285",
"DDInter649"
] | Nevirapine | Enzalutamide | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
188,
24,
129
]
],
[
[
188,
6,
8374
],
[
8374,
45,
129
]
],
[
[
188,
21,
28703
],
[
28703,
60,
129
]
],
[
[
188,
23,
608
],
[
608,
23,
129
]
],
[
[
188,
25,
1510
],
[
1510,
24,
129
]
],
[
[
188,
24,
79
],
[
79,
24,
129
]
],
[
[
188,
24,
1320
],
[
1320,
63,
129
]
],
[
[
188,
23,
1101
],
[
1101,
24,
129
]
],
[
[
188,
63,
600
],
[
600,
24,
129
]
],
[
[
188,
24,
351
],
[
351,
64,
129
]
]
] | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Nevirapine",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
]
] | Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Nevirapine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Nevirapine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Enzalutamide |
DB00852 | DB00865 | 1,445 | 939 | [
"DDInter1545",
"DDInter187"
] | Pseudoephedrine | Benzphetamine | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927. | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Moderate | 1 | [
[
[
1445,
24,
939
]
],
[
[
1445,
35,
1529
],
[
1529,
1,
939
]
],
[
[
1445,
63,
80
],
[
80,
40,
939
]
],
[
[
1445,
36,
1161
],
[
1161,
40,
939
]
],
[
[
1445,
63,
847
],
[
847,
1,
939
]
],
[
[
1445,
6,
2437
],
[
2437,
45,
939
]
],
[
[
1445,
21,
28762
],
[
28762,
60,
939
]
],
[
[
1445,
63,
1179
],
[
1179,
24,
939
]
],
[
[
1445,
24,
761
],
[
761,
63,
939
]
],
[
[
1445,
1,
22
],
[
22,
63,
939
]
]
] | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A3"
],
[
"SLC6A3",
"{u} (Gene) is bound by {v} (Compound)",
"Benzphetamine"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Benzphetamine"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) resembles {v} (Compound)",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]
]
] | Pseudoephedrine (Compound) resembles Metamfetamine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Benzphetamine (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Benzphetamine (Compound)
Pseudoephedrine (Compound) resembles Selegiline (Compound) and Pseudoephedrine may lead to a major life threatening interaction when taken with Selegiline and Selegiline (Compound) resembles Benzphetamine (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Benzphetamine (Compound)
Pseudoephedrine (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Benzphetamine (Compound)
Pseudoephedrine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Benzphetamine (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine
Pseudoephedrine (Compound) resembles Ephedrine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine |
DB01249 | DB14509 | 258 | 1,399 | [
"DDInter958",
"DDInter1081"
] | Iodixanol | Lithium carbonate | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Major | 2 | [
[
[
258,
25,
1399
]
],
[
[
258,
64,
589
],
[
589,
23,
1399
]
],
[
[
258,
24,
1574
],
[
1574,
23,
1399
]
],
[
[
258,
64,
387
],
[
387,
24,
1399
]
],
[
[
258,
24,
116
],
[
116,
24,
1399
]
],
[
[
258,
25,
712
],
[
712,
24,
1399
]
],
[
[
258,
64,
1512
],
[
1512,
25,
1399
]
],
[
[
258,
40,
497
],
[
497,
25,
1399
]
],
[
[
258,
64,
589
],
[
589,
24,
1555
],
[
1555,
24,
1399
]
],
[
[
258,
24,
1574
],
[
1574,
24,
1344
],
[
1344,
24,
1399
]
]
] | [
[
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iodixanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
],
[
"Urea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acyclovir"
],
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iodixanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
],
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iodixanol",
"{u} (Compound) resembles {v} (Compound)",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iodixanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
],
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
]
] | Iodixanol may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Iodixanol may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Iodixanol may lead to a major life threatening interaction when taken with Acyclovir and Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Iodixanol may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Iodixanol may lead to a major life threatening interaction when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Iodixanol may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Lithium carbonate
Iodixanol (Compound) resembles Iohexol (Compound) and Iohexol may lead to a major life threatening interaction when taken with Lithium carbonate
Iodixanol may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Iodixanol may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate |
DB00881 | DB01234 | 954 | 1,220 | [
"DDInter1554",
"DDInter513"
] | Quinapril | Dexamethasone | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Quinapril was granted FDA approval on 19 November 1991. A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Moderate | 1 | [
[
[
954,
24,
1220
]
],
[
[
954,
63,
870
],
[
870,
1,
1220
]
],
[
[
954,
63,
175
],
[
175,
40,
1220
]
],
[
[
954,
24,
617
],
[
617,
40,
1220
]
],
[
[
954,
21,
28769
],
[
28769,
60,
1220
]
],
[
[
954,
23,
1117
],
[
1117,
62,
1220
]
],
[
[
954,
24,
959
],
[
959,
24,
1220
]
],
[
[
954,
24,
1254
],
[
1254,
63,
1220
]
],
[
[
954,
63,
663
],
[
663,
24,
1220
]
],
[
[
954,
23,
286
],
[
286,
63,
1220
]
]
] | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Quinapril",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
],
[
"Sodium bicarbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
]
] | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Dexamethasone (Compound)
Quinapril (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Dexamethasone (Compound)
Quinapril may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate and Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone |
DB08870 | DB12001 | 850 | 564 | [
"DDInter228",
"DDInter7"
] | Brentuximab vedotin | Abemaciclib | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with . Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. | Moderate | 1 | [
[
[
850,
24,
564
]
],
[
[
850,
24,
868
],
[
868,
24,
564
]
],
[
[
850,
63,
58
],
[
58,
24,
564
]
],
[
[
850,
24,
1017
],
[
1017,
63,
564
]
],
[
[
850,
24,
68
],
[
68,
64,
564
]
],
[
[
850,
64,
1011
],
[
1011,
25,
564
]
],
[
[
850,
24,
913
],
[
913,
25,
564
]
],
[
[
850,
25,
1259
],
[
1259,
25,
564
]
],
[
[
850,
63,
215
],
[
215,
25,
564
]
],
[
[
850,
25,
779
],
[
779,
64,
564
]
]
] | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
],
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
]
] | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and Troleandomycin may lead to a major life threatening interaction when taken with Abemaciclib
Brentuximab vedotin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Abemaciclib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Abemaciclib
Brentuximab vedotin may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Abemaciclib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir may lead to a major life threatening interaction when taken with Abemaciclib
Brentuximab vedotin may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Abemaciclib |
DB00762 | DB01059 | 613 | 956 | [
"DDInter973",
"DDInter1313"
] | Irinotecan | Norfloxacin | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde). | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
613,
23,
956
]
],
[
[
613,
23,
872
],
[
872,
40,
956
]
],
[
[
613,
62,
1176
],
[
1176,
1,
956
]
],
[
[
613,
23,
1539
],
[
1539,
1,
956
]
],
[
[
613,
6,
6799
],
[
6799,
45,
956
]
],
[
[
613,
18,
3199
],
[
3199,
45,
956
]
],
[
[
613,
18,
8781
],
[
8781,
46,
956
]
],
[
[
613,
18,
2201
],
[
2201,
57,
956
]
],
[
[
613,
21,
29196
],
[
29196,
60,
956
]
],
[
[
613,
24,
869
],
[
869,
23,
956
]
]
] | [
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Irinotecan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Irinotecan",
"{u} (Compound) downregulates {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is bound by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Irinotecan",
"{u} (Compound) downregulates {v} (Gene)",
"ST7"
],
[
"ST7",
"{u} (Gene) is upregulated by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Irinotecan",
"{u} (Compound) downregulates {v} (Gene)",
"PPP2R5E"
],
[
"PPP2R5E",
"{u} (Gene) is downregulated by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Irinotecan",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
]
] | Irinotecan may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound)
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin (Compound) resembles Norfloxacin (Compound)
Irinotecan (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Norfloxacin (Compound)
Irinotecan (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Norfloxacin (Compound)
Irinotecan (Compound) downregulates ST7 (Gene) and ST7 (Gene) is upregulated by Norfloxacin (Compound)
Irinotecan (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Norfloxacin (Compound)
Irinotecan (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Norfloxacin (Compound)
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin |
DB00704 | DB00987 | 267 | 1,224 | [
"DDInter1263",
"DDInter460"
] | Naltrexone | Cytarabine | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) | Moderate | 1 | [
[
[
267,
24,
1224
]
],
[
[
267,
7,
2900
],
[
2900,
46,
1224
]
],
[
[
267,
18,
2183
],
[
2183,
57,
1224
]
],
[
[
267,
63,
1176
],
[
1176,
23,
1224
]
],
[
[
267,
63,
322
],
[
322,
24,
1224
]
],
[
[
267,
24,
287
],
[
287,
63,
1224
]
],
[
[
267,
24,
611
],
[
611,
24,
1224
]
],
[
[
267,
63,
1101
],
[
1101,
25,
1224
]
],
[
[
267,
25,
1510
],
[
1510,
64,
1224
]
],
[
[
267,
24,
1011
],
[
1011,
64,
1224
]
]
] | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Naltrexone",
"{u} (Compound) upregulates {v} (Gene)",
"NFKBIA"
],
[
"NFKBIA",
"{u} (Gene) is upregulated by {v} (Compound)",
"Cytarabine"
]
],
[
[
"Naltrexone",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Cytarabine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cytarabine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
],
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cytarabine"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cytarabine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cytarabine"
]
]
] | Naltrexone (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Cytarabine (Compound)
Naltrexone (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Cytarabine (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine and Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Cytarabine
Naltrexone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Cytarabine
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Cytarabine |
DB00902 | DB01037 | 104 | 1,161 | [
"DDInter1168",
"DDInter1653"
] | Methdilazine | Selegiline | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. | Moderate | 1 | [
[
[
104,
24,
1161
]
],
[
[
104,
63,
551
],
[
551,
1,
1161
]
],
[
[
104,
24,
1529
],
[
1529,
1,
1161
]
],
[
[
104,
63,
80
],
[
80,
40,
1161
]
],
[
[
104,
24,
633
],
[
633,
40,
1161
]
],
[
[
104,
24,
1411
],
[
1411,
63,
1161
]
],
[
[
104,
63,
176
],
[
176,
24,
1161
]
],
[
[
104,
24,
473
],
[
473,
24,
1161
]
],
[
[
104,
40,
820
],
[
820,
63,
1161
]
],
[
[
104,
25,
1311
],
[
1311,
63,
1161
]
]
] | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} (Compound) resembles {v} (Compound)",
"Selegiline"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Selegiline"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Selegiline"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
],
[
"Lisdexamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Selegiline"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Methdilazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
]
] | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Selegiline (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Selegiline (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Lisdexamfetamine and Lisdexamfetamine (Compound) resembles Selegiline (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Selegiline
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Selegiline
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Selegiline
Methdilazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Selegiline
Methdilazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Selegiline |
DB00350 | DB01284 | 1,214 | 1,042 | [
"DDInter1226",
"DDInter1782"
] | Minoxidil | Tetracosactide | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | Moderate | 1 | [
[
[
1214,
24,
1042
]
],
[
[
1214,
24,
1664
],
[
1664,
24,
1042
]
],
[
[
1214,
24,
607
],
[
607,
63,
1042
]
],
[
[
1214,
64,
1000
],
[
1000,
24,
1042
]
],
[
[
1214,
25,
1150
],
[
1150,
24,
1042
]
],
[
[
1214,
63,
1648
],
[
1648,
24,
1042
]
],
[
[
1214,
24,
593
],
[
593,
25,
1042
]
],
[
[
1214,
24,
1664
],
[
1664,
24,
455
],
[
455,
23,
1042
]
],
[
[
1214,
24,
607
],
[
607,
63,
455
],
[
455,
23,
1042
]
],
[
[
1214,
64,
1000
],
[
1000,
24,
1148
],
[
1148,
23,
1042
]
]
] | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Minoxidil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guanadrel"
],
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Minoxidil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guanethidine"
],
[
"Guanethidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Minoxidil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guanadrel"
],
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
]
] | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride and Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Minoxidil may lead to a major life threatening interaction when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Minoxidil may lead to a major life threatening interaction when taken with Guanethidine and Guanethidine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Tetracosactide
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride and Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Minoxidil may lead to a major life threatening interaction when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Tetracosactide |
DB00209 | DB01403 | 352 | 9 | [
"DDInter1886",
"DDInter1175"
] | Trospium | Methotrimeprazine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007. | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
352,
24,
9
]
],
[
[
352,
24,
1178
],
[
1178,
40,
9
]
],
[
[
352,
24,
1164
],
[
1164,
1,
9
]
],
[
[
352,
24,
401
],
[
401,
24,
9
]
],
[
[
352,
6,
2720
],
[
2720,
45,
9
]
],
[
[
352,
21,
28786
],
[
28786,
60,
9
]
],
[
[
352,
35,
1192
],
[
1192,
24,
9
]
],
[
[
352,
24,
407
],
[
407,
63,
9
]
],
[
[
352,
25,
1621
],
[
1621,
25,
9
]
],
[
[
352,
24,
1311
],
[
1311,
25,
9
]
]
] | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Trospium",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Trospium",
"{u} (Compound) causes {v} (Side Effect)",
"Urinary retention"
],
[
"Urinary retention",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Trospium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Trospium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrimeprazine"
]
]
] | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Methotrimeprazine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Trospium (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Methotrimeprazine (Compound)
Trospium (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Methotrimeprazine (Compound)
Trospium (Compound) resembles Glycopyrronium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Trospium may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Methotrimeprazine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Methotrimeprazine |
DB00196 | DB00317 | 600 | 883 | [
"DDInter743",
"DDInter810"
] | Fluconazole | Gefitinib | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Moderate | 1 | [
[
[
600,
24,
883
]
],
[
[
600,
25,
594
],
[
594,
40,
883
]
],
[
[
600,
25,
1069
],
[
1069,
1,
883
]
],
[
[
600,
6,
7524
],
[
7524,
45,
883
]
],
[
[
600,
18,
7847
],
[
7847,
57,
883
]
],
[
[
600,
21,
29340
],
[
29340,
60,
883
]
],
[
[
600,
23,
307
],
[
307,
62,
883
]
],
[
[
600,
24,
211
],
[
211,
62,
883
]
],
[
[
600,
25,
1593
],
[
1593,
63,
883
]
],
[
[
600,
23,
1627
],
[
1627,
63,
883
]
]
] | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} (Compound) resembles {v} (Compound)",
"Gefitinib"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} (Compound) resembles {v} (Compound)",
"Gefitinib"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Gefitinib"
]
],
[
[
"Fluconazole",
"{u} (Compound) downregulates {v} (Gene)",
"BAG3"
],
[
"BAG3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Gefitinib"
]
],
[
[
"Fluconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Stevens-Johnson syndrome"
],
[
"Stevens-Johnson syndrome",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gefitinib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gefitinib"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gefitinib"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
]
]
] | Fluconazole may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib (Compound) resembles Gefitinib (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib (Compound) resembles Gefitinib (Compound)
Fluconazole (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Gefitinib (Compound)
Fluconazole (Compound) downregulates BAG3 (Gene) and BAG3 (Gene) is downregulated by Gefitinib (Compound)
Fluconazole (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Gefitinib (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Gefitinib
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Gefitinib
Fluconazole may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib |
DB00792 | DB01589 | 832 | 481 | [
"DDInter1878",
"DDInter1552"
] | Tripelennamine | Quazepam | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other receptors. | Moderate | 1 | [
[
[
832,
24,
481
]
],
[
[
832,
63,
1216
],
[
1216,
1,
481
]
],
[
[
832,
24,
1418
],
[
1418,
1,
481
]
],
[
[
832,
63,
905
],
[
905,
40,
481
]
],
[
[
832,
24,
1532
],
[
1532,
24,
481
]
],
[
[
832,
63,
1614
],
[
1614,
24,
481
]
],
[
[
832,
24,
407
],
[
407,
63,
481
]
],
[
[
832,
74,
662
],
[
662,
24,
481
]
],
[
[
832,
35,
272
],
[
272,
24,
481
]
],
[
[
832,
40,
649
],
[
649,
63,
481
]
]
] | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
"Estazolam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorazepam"
],
[
"Lorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
]
] | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Quazepam (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Quazepam (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Quazepam
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Quazepam
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Quazepam
Tripelennamine (Compound) resembles Carbinoxamine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam
Tripelennamine (Compound) resembles Chlorpheniramine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam
Tripelennamine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Quazepam |
DB01017 | DB05528 | 1,669 | 1,070 | [
"DDInter1224",
"DDInter1228"
] | Minocycline | Mipomersen | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. Minocycline was granted FDA approval on 30 June 1971. | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications. It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. Specifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program. | Major | 2 | [
[
[
1669,
25,
1070
]
],
[
[
1669,
64,
1517
],
[
1517,
25,
1070
]
],
[
[
1669,
24,
384
],
[
384,
64,
1070
]
],
[
[
1669,
40,
1620
],
[
1620,
25,
1070
]
],
[
[
1669,
25,
1510
],
[
1510,
64,
1070
]
],
[
[
1669,
63,
1560
],
[
1560,
25,
1070
]
],
[
[
1669,
25,
1377
],
[
1377,
25,
1070
]
],
[
[
1669,
1,
1545
],
[
1545,
25,
1070
]
],
[
[
1669,
64,
1517
],
[
1517,
24,
384
],
[
384,
64,
1070
]
],
[
[
1669,
24,
384
],
[
384,
63,
292
],
[
292,
64,
1070
]
]
] | [
[
[
"Minocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Minocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Minocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Minocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Minocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
]
] | Minocycline may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Mipomersen
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Mipomersen
Minocycline (Compound) resembles Tetracycline (Compound) and Tetracycline may lead to a major life threatening interaction when taken with Mipomersen
Minocycline may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Mipomersen
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may lead to a major life threatening interaction when taken with Mipomersen
Minocycline may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Mipomersen
Minocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may lead to a major life threatening interaction when taken with Mipomersen
Minocycline may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Mipomersen
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen |
DB04865 | DB14409 | 4 | 1,129 | [
"DDInter1335",
"DDInter867"
] | Omacetaxine mepesuccinate | Human adenovirus e serotype 4 strain cl-68578 antigen | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
4,
24,
1129
]
],
[
[
4,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
4,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
4,
63,
134
],
[
134,
24,
1129
]
],
[
[
4,
25,
1259
],
[
1259,
24,
1129
]
],
[
[
4,
25,
676
],
[
676,
63,
1129
]
],
[
[
4,
24,
994
],
[
994,
63,
1129
]
],
[
[
4,
64,
1057
],
[
1057,
25,
1683
],
[
1683,
24,
1129
]
],
[
[
4,
24,
1683
],
[
1683,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
4,
63,
134
],
[
134,
64,
1057
],
[
1057,
24,
1129
]
]
] | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
],
[
"Risankizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
]
] | Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab and Risankizumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen |
DB01118 | DB06772 | 33 | 310 | [
"DDInter76",
"DDInter259"
] | Amiodarone | Cabazitaxel | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286] | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019. | Moderate | 1 | [
[
[
33,
24,
310
]
],
[
[
33,
24,
973
],
[
973,
24,
310
]
],
[
[
33,
6,
7524
],
[
7524,
45,
310
]
],
[
[
33,
21,
28894
],
[
28894,
60,
310
]
],
[
[
33,
25,
868
],
[
868,
63,
310
]
],
[
[
33,
63,
896
],
[
896,
24,
310
]
],
[
[
33,
24,
350
],
[
350,
63,
310
]
],
[
[
33,
25,
1213
],
[
1213,
24,
310
]
],
[
[
33,
64,
79
],
[
79,
24,
310
]
],
[
[
33,
40,
540
],
[
540,
24,
310
]
]
] | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Amiodarone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Amiodarone",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure"
],
[
"Cardiac failure",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Amiodarone",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
]
] | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Amiodarone (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cabazitaxel (Compound)
Amiodarone (Compound) causes Cardiac failure (Side Effect) and Cardiac failure (Side Effect) is caused by Cabazitaxel (Compound)
Amiodarone may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Amiodarone may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Amiodarone may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Amiodarone (Compound) resembles Dronedarone (Compound) and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel |
DB01070 | DB11110 | 1,098 | 603 | [
"DDInter558",
"DDInter1115"
] | Dihydrotachysterol | Magnesium citrate | A vitamin D that can be regarded as a reduction product of vitamin D2. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products. | Moderate | 1 | [
[
[
1098,
24,
603
]
],
[
[
1098,
25,
1196
],
[
1196,
24,
603
]
],
[
[
1098,
63,
544
],
[
544,
24,
603
]
],
[
[
1098,
75,
1331
],
[
1331,
24,
603
]
],
[
[
1098,
64,
1041
],
[
1041,
24,
603
]
],
[
[
1098,
24,
853
],
[
853,
24,
603
]
],
[
[
1098,
25,
241
],
[
241,
64,
603
]
],
[
[
1098,
25,
1196
],
[
1196,
63,
674
],
[
674,
24,
603
]
],
[
[
1098,
63,
544
],
[
544,
23,
16
],
[
16,
23,
603
]
],
[
[
1098,
63,
1605
],
[
1605,
25,
57
],
[
57,
24,
603
]
]
] | [
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Dihydrotachysterol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Ergocalciferol"
],
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
],
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
],
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
],
[
"Erdafitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
],
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
]
] | Dihydrotachysterol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Dihydrotachysterol (Compound) resembles Ergocalciferol (Compound) and Dihydrotachysterol may lead to a major life threatening interaction when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Dihydrotachysterol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Dihydrotachysterol may lead to a major life threatening interaction when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Magnesium citrate
Dihydrotachysterol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Magnesium citrate
Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate |
DB00802 | DB14568 | 1,322 | 982 | [
"DDInter43",
"DDInter1000"
] | Alfentanil | Ivosidenib | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Moderate | 1 | [
[
[
1322,
24,
982
]
],
[
[
1322,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1322,
62,
608
],
[
608,
23,
982
]
],
[
[
1322,
24,
976
],
[
976,
24,
982
]
],
[
[
1322,
24,
159
],
[
159,
63,
982
]
],
[
[
1322,
40,
1454
],
[
1454,
24,
982
]
],
[
[
1322,
24,
1250
],
[
1250,
25,
982
]
],
[
[
1322,
64,
600
],
[
600,
25,
982
]
],
[
[
1322,
25,
1133
],
[
1133,
25,
982
]
],
[
[
1322,
63,
888
],
[
888,
25,
982
]
]
] | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Alfentanil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Alfentanil",
"{u} (Compound) resembles {v} (Compound)",
"Sufentanil"
],
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
]
] | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Alfentanil may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Alfentanil (Compound) resembles Sufentanil (Compound) and Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Ivosidenib
Alfentanil may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib
Alfentanil may lead to a major life threatening interaction when taken with Granisetron and Granisetron may lead to a major life threatening interaction when taken with Ivosidenib
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Ivosidenib |
DB01583 | DB13142 | 624 | 841 | [
"DDInter1075",
"DDInter274"
] | Liotrix | Calcium glubionate anhydrous | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion. It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues. Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage. In fact, administration of T3 may result in supratherapeutic levels of T3. | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
624,
24,
841
]
],
[
[
624,
40,
1152
],
[
1152,
24,
841
]
],
[
[
624,
1,
542
],
[
542,
24,
841
]
],
[
[
624,
63,
1231
],
[
1231,
24,
841
]
],
[
[
624,
40,
1152
],
[
1152,
24,
1436
],
[
1436,
24,
841
]
],
[
[
624,
1,
542
],
[
542,
24,
1436
],
[
1436,
24,
841
]
],
[
[
624,
63,
1283
],
[
1283,
24,
255
],
[
255,
24,
841
]
],
[
[
624,
1,
542
],
[
542,
63,
1252
],
[
1252,
24,
841
]
],
[
[
624,
63,
1283
],
[
1283,
25,
1436
],
[
1436,
24,
841
]
],
[
[
624,
63,
1231
],
[
1231,
63,
1252
],
[
1252,
24,
841
]
]
] | [
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Liotrix",
"{u} (Compound) resembles {v} (Compound)",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Liotrix",
"{u} (Compound) resembles {v} (Compound)",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Liotrix",
"{u} (Compound) resembles {v} (Compound)",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
],
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Liotrix",
"{u} (Compound) resembles {v} (Compound)",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
],
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Liotrix",
"{u} (Compound) resembles {v} (Compound)",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Patiromer"
],
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
]
] | Liotrix (Compound) resembles Liothyronine (Compound) and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Liotrix (Compound) resembles Levothyroxine (Compound) and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Liotrix (Compound) resembles Liothyronine (Compound) and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Liotrix (Compound) resembles Levothyroxine (Compound) and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Liotrix (Compound) resembles Levothyroxine (Compound) and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may lead to a major life threatening interaction when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous |
DB01236 | DB09330 | 679 | 985 | [
"DDInter1664",
"DDInter1352"
] | Sevoflurane | Osimertinib | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Major | 2 | [
[
[
679,
25,
985
]
],
[
[
679,
62,
112
],
[
112,
23,
985
]
],
[
[
679,
63,
480
],
[
480,
24,
985
]
],
[
[
679,
24,
657
],
[
657,
63,
985
]
],
[
[
679,
24,
28
],
[
28,
24,
985
]
],
[
[
679,
64,
11
],
[
11,
25,
985
]
],
[
[
679,
24,
594
],
[
594,
25,
985
]
],
[
[
679,
25,
1069
],
[
1069,
25,
985
]
],
[
[
679,
24,
484
],
[
484,
64,
985
]
],
[
[
679,
63,
1674
],
[
1674,
25,
985
]
]
] | [
[
[
"Sevoflurane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Sevoflurane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Sevoflurane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Sevoflurane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
]
] | Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Sevoflurane may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Osimertinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Osimertinib
Sevoflurane may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Osimertinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Osimertinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may lead to a major life threatening interaction when taken with Osimertinib |
DB00432 | DB11003 | 1,083 | 748 | [
"DDInter1868",
"DDInter100"
] | Trifluridine | Anthrax vaccine | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity against Herpes simplex virus type 1 and 2. The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In the anticancer therapy, trifluridine acts as a thymidine-based nucleoside metabolic inhibitor that gets | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
1083,
24,
748
]
],
[
[
1083,
25,
676
],
[
676,
63,
748
]
],
[
[
1083,
24,
1683
],
[
1683,
24,
748
]
],
[
[
1083,
64,
1057
],
[
1057,
24,
748
]
],
[
[
1083,
24,
270
],
[
270,
63,
748
]
],
[
[
1083,
25,
1011
],
[
1011,
24,
748
]
],
[
[
1083,
40,
1238
],
[
1238,
24,
748
]
],
[
[
1083,
75,
1064
],
[
1064,
24,
748
]
],
[
[
1083,
63,
66
],
[
66,
24,
748
]
],
[
[
1083,
25,
676
],
[
676,
64,
322
],
[
322,
24,
748
]
]
] | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound)",
"Pentostatin"
],
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
]
] | Trifluridine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Trifluridine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Trifluridine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Trifluridine (Compound) resembles Pentostatin (Compound) and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Trifluridine (Compound) resembles Cladribine (Compound) and Trifluridine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Trifluridine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
DB00377 | DB00679 | 1,494 | 684 | [
"DDInter1382",
"DDInter1796"
] | Palonosetron | Thioridazine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias. | Major | 2 | [
[
[
1494,
25,
684
]
],
[
[
1494,
25,
1237
],
[
1237,
40,
684
]
],
[
[
1494,
24,
216
],
[
216,
1,
684
]
],
[
[
1494,
6,
12523
],
[
12523,
45,
684
]
],
[
[
1494,
21,
28680
],
[
28680,
60,
684
]
],
[
[
1494,
23,
112
],
[
112,
62,
684
]
],
[
[
1494,
24,
770
],
[
770,
63,
684
]
],
[
[
1494,
25,
506
],
[
506,
24,
684
]
],
[
[
1494,
25,
222
],
[
222,
63,
684
]
],
[
[
1494,
24,
355
],
[
355,
24,
684
]
]
] | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Thioridazine"
]
],
[
[
"Palonosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thioridazine"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thioridazine"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
]
]
] | Palonosetron may lead to a major life threatening interaction when taken with Clomipramine and Clomipramine (Compound) resembles Thioridazine (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Thioridazine (Compound)
Palonosetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Thioridazine (Compound)
Palonosetron (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Thioridazine (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Thioridazine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine
Palonosetron may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine
Palonosetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine |
DB01044 | DB01128 | 246 | 918 | [
"DDInter809",
"DDInter204"
] | Gatifloxacin | Bicalutamide | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Major | 2 | [
[
[
246,
25,
918
]
],
[
[
246,
25,
129
],
[
129,
40,
918
]
],
[
[
246,
21,
28642
],
[
28642,
60,
918
]
],
[
[
246,
62,
112
],
[
112,
23,
918
]
],
[
[
246,
64,
126
],
[
126,
23,
918
]
],
[
[
246,
25,
392
],
[
392,
63,
918
]
],
[
[
246,
64,
473
],
[
473,
24,
918
]
],
[
[
246,
63,
663
],
[
663,
24,
918
]
],
[
[
246,
1,
956
],
[
956,
24,
918
]
],
[
[
246,
25,
1520
],
[
1520,
24,
918
]
]
] | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} (Compound) resembles {v} (Compound)",
"Bicalutamide"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bicalutamide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bicalutamide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bicalutamide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
]
] | Gatifloxacin may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Gatifloxacin (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Bicalutamide (Compound)
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bicalutamide
Gatifloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Bicalutamide
Gatifloxacin may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Gatifloxacin may lead to a major life threatening interaction when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Gatifloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Gatifloxacin may lead to a major life threatening interaction when taken with Primaquine and Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide |
DB00295 | DB01178 | 475 | 369 | [
"DDInter1244",
"DDInter357"
] | Morphine | Chlormezanone | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. | Major | 2 | [
[
[
475,
25,
369
]
],
[
[
475,
24,
1532
],
[
1532,
63,
369
]
],
[
[
475,
24,
272
],
[
272,
24,
369
]
],
[
[
475,
63,
701
],
[
701,
24,
369
]
],
[
[
475,
25,
593
],
[
593,
24,
369
]
],
[
[
475,
24,
1532
],
[
1532,
63,
272
],
[
272,
24,
369
]
],
[
[
475,
24,
272
],
[
272,
24,
1532
],
[
1532,
63,
369
]
],
[
[
475,
24,
13
],
[
13,
7,
7248
],
[
7248,
46,
369
]
],
[
[
475,
63,
701
],
[
701,
18,
4930
],
[
4930,
57,
369
]
],
[
[
475,
24,
407
],
[
407,
63,
1532
],
[
1532,
63,
369
]
]
] | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlormezanone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} (Compound) upregulates {v} (Gene)",
"RPP38"
],
[
"RPP38",
"{u} (Gene) is upregulated by {v} (Compound)",
"Chlormezanone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
"Chlormezanone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
]
] | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Morphine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine (Compound) upregulates RPP38 (Gene) and RPP38 (Gene) is upregulated by Chlormezanone (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Chlormezanone (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone |
DB00497 | DB11718 | 828 | 927 | [
"DDInter1366",
"DDInter640"
] | Oxycodone | Encorafenib | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
828,
24,
927
]
],
[
[
828,
63,
1324
],
[
1324,
24,
927
]
],
[
[
828,
24,
1264
],
[
1264,
24,
927
]
],
[
[
828,
25,
1374
],
[
1374,
24,
927
]
],
[
[
828,
24,
1259
],
[
1259,
63,
927
]
],
[
[
828,
40,
1516
],
[
1516,
24,
927
]
],
[
[
828,
64,
1051
],
[
1051,
24,
927
]
],
[
[
828,
25,
1320
],
[
1320,
63,
927
]
],
[
[
828,
64,
597
],
[
597,
25,
927
]
],
[
[
828,
25,
1017
],
[
1017,
64,
927
]
]
] | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Galantamine"
],
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
]
] | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Oxycodone may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Oxycodone (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Oxycodone may lead to a major life threatening interaction when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Oxycodone may lead to a major life threatening interaction when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Oxycodone may lead to a major life threatening interaction when taken with Chloramphenicol and Chloramphenicol may lead to a major life threatening interaction when taken with Encorafenib
Oxycodone may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Encorafenib |
DB00860 | DB11642 | 891 | 938 | [
"DDInter1513",
"DDInter1480"
] | Prednisolone | Pitolisant | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults. | Moderate | 1 | [
[
[
891,
24,
938
]
],
[
[
891,
24,
760
],
[
760,
24,
938
]
],
[
[
891,
63,
600
],
[
600,
24,
938
]
],
[
[
891,
62,
1018
],
[
1018,
24,
938
]
],
[
[
891,
1,
617
],
[
617,
24,
938
]
],
[
[
891,
40,
870
],
[
870,
24,
938
]
],
[
[
891,
23,
1148
],
[
1148,
24,
938
]
],
[
[
891,
24,
283
],
[
283,
63,
938
]
],
[
[
891,
25,
676
],
[
676,
63,
938
]
],
[
[
891,
25,
770
],
[
770,
24,
938
]
]
] | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
]
] | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Prednisolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Prednisolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Prednisolone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Prednisolone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant |
DB00436 | DB09038 | 323 | 1,450 | [
"DDInter179",
"DDInter636"
] | Bendroflumethiazide | Empagliflozin | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916] | Moderate | 1 | [
[
[
323,
24,
1450
]
],
[
[
323,
24,
659
],
[
659,
63,
1450
]
],
[
[
323,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
323,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
323,
40,
178
],
[
178,
24,
1450
]
],
[
[
323,
24,
659
],
[
659,
64,
461
],
[
461,
24,
1450
]
],
[
[
323,
63,
1061
],
[
1061,
63,
461
],
[
461,
24,
1450
]
],
[
[
323,
24,
1486
],
[
1486,
63,
461
],
[
461,
24,
1450
]
],
[
[
323,
63,
1179
],
[
1179,
23,
1103
],
[
1103,
23,
1450
]
],
[
[
323,
24,
870
],
[
870,
1,
1103
],
[
1103,
23,
1450
]
]
] | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Empagliflozin"
]
]
] | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Bendroflumethiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may lead to a major life threatening interaction when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin |
DB00460 | DB01612 | 612 | 1,637 | [
"DDInter1929",
"DDInter92"
] | Verteporfin | Amyl Nitrite | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels. | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
612,
24,
1637
]
],
[
[
612,
24,
714
],
[
714,
24,
1637
]
],
[
[
612,
63,
1061
],
[
1061,
24,
1637
]
],
[
[
612,
24,
714
],
[
714,
24,
961
],
[
961,
63,
1637
]
],
[
[
612,
63,
1061
],
[
1061,
24,
697
],
[
697,
24,
1637
]
],
[
[
612,
24,
401
],
[
401,
63,
946
],
[
946,
24,
1637
]
],
[
[
612,
21,
28845
],
[
28845,
60,
946
],
[
946,
24,
1637
]
],
[
[
612,
24,
714
],
[
714,
24,
1053
],
[
1053,
24,
1637
]
],
[
[
612,
63,
1061
],
[
1061,
24,
961
],
[
961,
63,
1637
]
],
[
[
612,
24,
885
],
[
885,
40,
1061
],
[
1061,
24,
1637
]
]
] | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
],
[
"Licorice",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Verteporfin",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Buspirone"
],
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
],
[
"Licorice",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} (Compound) resembles {v} (Compound)",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
]
] | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Licorice and Licorice may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Buspirone and Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Verteporfin (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Buspirone (Compound) and Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Licorice and Licorice may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite |
DB00456 | DB01082 | 164 | 1,448 | [
"DDInter311",
"DDInter1713"
] | Cefalotin | Streptomycin | Cefalotin is a cephalosporin antibiotic. | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis. | Moderate | 1 | [
[
[
164,
24,
1448
]
],
[
[
164,
6,
10612
],
[
10612,
45,
1448
]
],
[
[
164,
24,
361
],
[
361,
24,
1448
]
],
[
[
164,
40,
1558
],
[
1558,
63,
1448
]
],
[
[
164,
24,
1662
],
[
1662,
63,
1448
]
],
[
[
164,
40,
1087
],
[
1087,
24,
1448
]
],
[
[
164,
24,
416
],
[
416,
74,
1448
]
],
[
[
164,
6,
10612
],
[
10612,
45,
1027
],
[
1027,
24,
1448
]
],
[
[
164,
24,
361
],
[
361,
1,
437
],
[
437,
40,
1448
]
],
[
[
164,
40,
1558
],
[
1558,
21,
28882
],
[
28882,
60,
1448
]
]
] | [
[
[
"Cefalotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Cefalotin",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Streptomycin"
]
],
[
[
"Cefalotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Cefalotin",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
],
[
"Cefoxitin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Cefalotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Cefalotin",
"{u} (Compound) resembles {v} (Compound)",
"Cefotaxime"
],
[
"Cefotaxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Cefalotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Cefalotin",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Piroxicam"
],
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Cefalotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} (Compound) resembles {v} (Compound)",
"Amikacin"
],
[
"Amikacin",
"{u} (Compound) resembles {v} (Compound)",
"Streptomycin"
]
],
[
[
"Cefalotin",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
],
[
"Cefoxitin",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Streptomycin"
]
]
] | Cefalotin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Streptomycin (Compound)
Cefalotin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Cefalotin (Compound) resembles Cefoxitin (Compound) and Cefoxitin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Cefalotin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Cefalotin (Compound) resembles Cefotaxime (Compound) and Cefotaxime may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Cefalotin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Streptomycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Cefalotin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Piroxicam (Compound) and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Cefalotin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin (Compound) resembles Amikacin (Compound) and Amikacin (Compound) resembles Streptomycin (Compound)
Cefalotin (Compound) resembles Cefoxitin (Compound) and Cefoxitin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Streptomycin (Compound) |
DB00005 | DB00081 | 1,057 | 273 | [
"DDInter687",
"DDInter1838"
] | Etanercept | Tositumomab | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Major | 2 | [
[
[
1057,
25,
273
]
],
[
[
1057,
24,
1270
],
[
1270,
63,
273
]
],
[
[
1057,
25,
869
],
[
869,
63,
273
]
],
[
[
1057,
25,
1184
],
[
1184,
24,
273
]
],
[
[
1057,
25,
1137
],
[
1137,
64,
273
]
],
[
[
1057,
24,
126
],
[
126,
64,
273
]
],
[
[
1057,
25,
1172
],
[
1172,
25,
273
]
],
[
[
1057,
24,
1270
],
[
1270,
63,
869
],
[
869,
63,
273
]
],
[
[
1057,
24,
597
],
[
597,
24,
810
],
[
810,
63,
273
]
],
[
[
1057,
25,
869
],
[
869,
24,
810
],
[
810,
63,
273
]
]
] | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tositumomab"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tositumomab"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tositumomab"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tositumomab"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
],
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tositumomab"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tositumomab"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tositumomab"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tositumomab"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tositumomab"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tositumomab"
]
]
] | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab
Etanercept may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab
Etanercept may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab
Etanercept may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Tositumomab
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Tositumomab
Etanercept may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Tositumomab
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab
Etanercept may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab |
DB00054 | DB00176 | 1,432 | 529 | [
"DDInter6",
"DDInter770"
] | Abciximab | Fluvoxamine | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. | Moderate | 1 | [
[
[
1432,
24,
529
]
],
[
[
1432,
64,
20
],
[
20,
24,
529
]
],
[
[
1432,
24,
1274
],
[
1274,
63,
529
]
],
[
[
1432,
25,
1172
],
[
1172,
24,
529
]
],
[
[
1432,
25,
1421
],
[
1421,
63,
529
]
],
[
[
1432,
63,
942
],
[
942,
24,
529
]
],
[
[
1432,
24,
121
],
[
121,
64,
529
]
],
[
[
1432,
25,
1347
],
[
1347,
64,
529
]
],
[
[
1432,
64,
20
],
[
20,
24,
1274
],
[
1274,
63,
529
]
],
[
[
1432,
24,
1274
],
[
1274,
6,
6017
],
[
6017,
45,
529
]
]
] | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Fluvoxamine"
]
]
] | Abciximab may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Abciximab may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Abciximab may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine
Abciximab may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Fluvoxamine
Abciximab may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fluvoxamine (Compound) |
DB00574 | DB00813 | 121 | 704 | [
"DDInter717",
"DDInter722"
] | Fenfluramine | Fentanyl | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and [oxycodone]. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily. Fentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] | Major | 2 | [
[
[
121,
25,
704
]
],
[
[
121,
63,
194
],
[
194,
40,
704
]
],
[
[
121,
25,
939
],
[
939,
40,
704
]
],
[
[
121,
24,
998
],
[
998,
1,
704
]
],
[
[
121,
25,
1454
],
[
1454,
1,
704
]
],
[
[
121,
63,
576
],
[
576,
1,
704
]
],
[
[
121,
63,
1503
],
[
1503,
24,
704
]
],
[
[
121,
24,
1662
],
[
1662,
63,
704
]
],
[
[
121,
23,
173
],
[
173,
63,
704
]
],
[
[
121,
24,
1347
],
[
1347,
24,
704
]
]
] | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
],
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sufentanil"
],
[
"Sufentanil",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
],
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
]
],
[
[
"Fenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxone"
],
[
"Naloxone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
]
]
] | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Fentanyl (Compound)
Fenfluramine may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Fentanyl (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Fentanyl (Compound)
Fenfluramine may lead to a major life threatening interaction when taken with Sufentanil and Sufentanil (Compound) resembles Fentanyl (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Fentanyl (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Naloxone and Naloxone may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl |
DB00559 | DB12010 | 152 | 214 | [
"DDInter223",
"DDInter785"
] | Bosentan | Fostamatinib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
152,
24,
214
]
],
[
[
152,
24,
976
],
[
976,
24,
214
]
],
[
[
152,
25,
866
],
[
866,
24,
214
]
],
[
[
152,
63,
10
],
[
10,
24,
214
]
],
[
[
152,
24,
676
],
[
676,
63,
214
]
],
[
[
152,
25,
1017
],
[
1017,
63,
214
]
],
[
[
152,
62,
168
],
[
168,
24,
214
]
],
[
[
152,
24,
609
],
[
609,
25,
214
]
],
[
[
152,
25,
1510
],
[
1510,
25,
214
]
],
[
[
152,
24,
976
],
[
976,
63,
723
],
[
723,
24,
214
]
]
] | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bosentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
]
] | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Bosentan may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Bosentan may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fostamatinib
Bosentan may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Fostamatinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib |
DB01611 | DB13007 | 1,487 | 1,060 | [
"DDInter893",
"DDInter642"
] | Hydroxychloroquine | Enfortumab vedotin | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022. | Moderate | 1 | [
[
[
1487,
24,
1060
]
],
[
[
1487,
24,
1604
],
[
1604,
23,
1060
]
],
[
[
1487,
25,
1593
],
[
1593,
24,
1060
]
],
[
[
1487,
63,
590
],
[
590,
24,
1060
]
],
[
[
1487,
24,
1439
],
[
1439,
24,
1060
]
],
[
[
1487,
64,
600
],
[
600,
24,
1060
]
],
[
[
1487,
25,
1011
],
[
1011,
25,
1060
]
],
[
[
1487,
64,
1377
],
[
1377,
25,
1060
]
],
[
[
1487,
63,
581
],
[
581,
25,
1060
]
],
[
[
1487,
24,
760
],
[
760,
25,
1060
]
]
] | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
]
] | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Hydroxychloroquine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Hydroxychloroquine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Hydroxychloroquine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Enfortumab vedotin
Hydroxychloroquine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Enfortumab vedotin
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Enfortumab vedotin
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Enfortumab vedotin |
DB00959 | DB13928 | 1,486 | 1,385 | [
"DDInter1191",
"DDInter1660"
] | Methylprednisolone | Semaglutide | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective. | Moderate | 1 | [
[
[
1486,
24,
1385
]
],
[
[
1486,
64,
839
],
[
839,
24,
1385
]
],
[
[
1486,
24,
637
],
[
637,
24,
1385
]
],
[
[
1486,
63,
359
],
[
359,
24,
1385
]
],
[
[
1486,
40,
891
],
[
891,
24,
1385
]
],
[
[
1486,
25,
872
],
[
872,
24,
1385
]
],
[
[
1486,
23,
1148
],
[
1148,
24,
1385
]
],
[
[
1486,
24,
1412
],
[
1412,
63,
1385
]
],
[
[
1486,
1,
303
],
[
303,
24,
1385
]
],
[
[
1486,
62,
1674
],
[
1674,
24,
1385
]
]
] | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
],
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
]
] | Methylprednisolone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Methylprednisolone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Methylprednisolone may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Methylprednisolone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide |
DB00201 | DB12332 | 1,684 | 1,619 | [
"DDInter263",
"DDInter1626"
] | Caffeine | Rucaparib | Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection. The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999. According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1684,
24,
1619
]
],
[
[
1684,
24,
969
],
[
969,
24,
1619
]
],
[
[
1684,
23,
869
],
[
869,
24,
1619
]
],
[
[
1684,
24,
1399
],
[
1399,
63,
1619
]
],
[
[
1684,
25,
876
],
[
876,
25,
1619
]
],
[
[
1684,
24,
1163
],
[
1163,
25,
1619
]
],
[
[
1684,
23,
695
],
[
695,
25,
1619
]
],
[
[
1684,
24,
969
],
[
969,
24,
222
],
[
222,
23,
1619
]
],
[
[
1684,
24,
1362
],
[
1362,
64,
307
],
[
307,
23,
1619
]
],
[
[
1684,
24,
663
],
[
663,
24,
259
],
[
259,
24,
1619
]
]
] | [
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
],
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Caffeine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Caffeine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
],
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Caffeine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
],
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
]
] | Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon and Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Caffeine may cause a minor interaction that can limit clinical effects when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Caffeine may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Rucaparib
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline and Rasagiline may lead to a major life threatening interaction when taken with Rucaparib
Caffeine may cause a minor interaction that can limit clinical effects when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Rucaparib
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon and Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib |
DB01208 | DB11986 | 945 | 484 | [
"DDInter1705",
"DDInter648"
] | Sparfloxacin | Entrectinib | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Major | 2 | [
[
[
945,
25,
484
]
],
[
[
945,
62,
112
],
[
112,
23,
484
]
],
[
[
945,
40,
1539
],
[
1539,
24,
484
]
],
[
[
945,
25,
774
],
[
774,
24,
484
]
],
[
[
945,
64,
1674
],
[
1674,
24,
484
]
],
[
[
945,
62,
63
],
[
63,
24,
484
]
],
[
[
945,
24,
603
],
[
603,
24,
484
]
],
[
[
945,
63,
688
],
[
688,
24,
484
]
],
[
[
945,
25,
1619
],
[
1619,
63,
484
]
],
[
[
945,
25,
985
],
[
985,
25,
484
]
]
] | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
],
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
]
] | Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Sparfloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Sparfloxacin may lead to a major life threatening interaction when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Sparfloxacin may lead to a major life threatening interaction when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Sparfloxacin may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Sparfloxacin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Entrectinib |
DB00005 | DB00851 | 1,057 | 611 | [
"DDInter687",
"DDInter463"
] | Etanercept | Dacarbazine | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Major | 2 | [
[
[
1057,
25,
611
]
],
[
[
1057,
25,
141
],
[
141,
24,
611
]
],
[
[
1057,
25,
850
],
[
850,
63,
611
]
],
[
[
1057,
24,
66
],
[
66,
24,
611
]
],
[
[
1057,
24,
1270
],
[
1270,
63,
611
]
],
[
[
1057,
23,
1461
],
[
1461,
24,
611
]
],
[
[
1057,
25,
1648
],
[
1648,
25,
611
]
],
[
[
1057,
25,
770
],
[
770,
64,
611
]
],
[
[
1057,
25,
141
],
[
141,
23,
739
],
[
739,
62,
611
]
],
[
[
1057,
25,
850
],
[
850,
63,
1176
],
[
1176,
23,
611
]
]
] | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacarbazine"
]
]
] | Etanercept may lead to a major life threatening interaction when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Etanercept may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Etanercept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Etanercept may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Dacarbazine
Etanercept may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Dacarbazine
Etanercept may lead to a major life threatening interaction when taken with Floxuridine and Floxuridine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine
Etanercept may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine |
DB01105 | DB01125 | 222 | 279 | [
"DDInter1665",
"DDInter98"
] | Sibutramine | Anisindione | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver. | Moderate | 1 | [
[
[
222,
24,
279
]
],
[
[
222,
63,
1647
],
[
1647,
23,
279
]
],
[
[
222,
63,
1645
],
[
1645,
24,
279
]
],
[
[
222,
62,
522
],
[
522,
24,
279
]
],
[
[
222,
25,
593
],
[
593,
63,
279
]
],
[
[
222,
24,
578
],
[
578,
63,
279
]
],
[
[
222,
64,
121
],
[
121,
24,
279
]
],
[
[
222,
24,
1411
],
[
1411,
24,
279
]
],
[
[
222,
23,
1619
],
[
1619,
63,
279
]
],
[
[
222,
24,
1564
],
[
1564,
64,
279
]
]
] | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anisindione"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
]
] | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Anisindione
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sibutramine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sibutramine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide and Defibrotide may lead to a major life threatening interaction when taken with Anisindione |
DB00945 | DB09481 | 1,479 | 460 | [
"DDInter20",
"DDInter1113"
] | Acetylsalicylic acid | Magnesium carbonate | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label]. Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer. Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others. Acetylsalicylic acid is a very common | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
1479,
24,
460
]
],
[
[
1479,
63,
664
],
[
664,
23,
460
]
],
[
[
1479,
23,
1592
],
[
1592,
23,
460
]
],
[
[
1479,
62,
461
],
[
461,
23,
460
]
],
[
[
1479,
24,
1603
],
[
1603,
23,
460
]
],
[
[
1479,
25,
1468
],
[
1468,
23,
460
]
],
[
[
1479,
24,
872
],
[
872,
24,
460
]
],
[
[
1479,
25,
1213
],
[
1213,
24,
460
]
],
[
[
1479,
63,
245
],
[
245,
24,
460
]
],
[
[
1479,
25,
405
],
[
405,
63,
460
]
]
] | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
],
[
"Perindopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
],
[
"Captopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
]
] | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Nebivolol and Nebivolol may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Acetylsalicylic acid may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Acetylsalicylic acid may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Acetylsalicylic acid may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate |
DB00794 | DB01501 | 759 | 1,118 | [
"DDInter1521",
"DDInter549"
] | Primidone | Difenoxin | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a brand mixture which combines atropine sulfate and difenoxin hydrochloride. It is approved by the FDA to treat acute and chronic diarrhea. Difenoxin is an active metabolite of the anti-diarrheal drug, diphenoxylate, which is also used in combination with atropine in the brand mixture Lomotil(R). It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide it is still capable of crossing the blood brain barrier to produce weak sedative and analgesic effects. However, the antidiarrheal potency of difenoxin is much greater than its CNS effects, which makes it an attractive alternative to other opioids. | Moderate | 1 | [
[
[
759,
24,
1118
]
],
[
[
759,
24,
1688
],
[
1688,
40,
1118
]
],
[
[
759,
63,
506
],
[
506,
24,
1118
]
],
[
[
759,
1,
697
],
[
697,
24,
1118
]
],
[
[
759,
24,
1609
],
[
1609,
63,
1118
]
],
[
[
759,
24,
1688
],
[
1688,
40,
11264
],
[
11264,
40,
1118
]
],
[
[
759,
63,
506
],
[
506,
63,
576
],
[
576,
1,
1118
]
],
[
[
759,
1,
697
],
[
697,
63,
1688
],
[
1688,
40,
1118
]
],
[
[
759,
24,
1609
],
[
1609,
63,
576
],
[
576,
1,
1118
]
],
[
[
759,
24,
649
],
[
649,
1,
11264
],
[
11264,
40,
1118
]
]
] | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Diphenidol"
],
[
"Diphenidol",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Diphenidol"
],
[
"Diphenidol",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
]
] | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Difenoxin (Compound)
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin
Primidone (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Difenoxin (Compound)
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Difenoxin (Compound)
Primidone (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Difenoxin (Compound)
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Difenoxin (Compound)
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Difenoxin (Compound) |
DB01176 | DB06691 | 537 | 849 | [
"DDInter453",
"DDInter1155"
] | Cyclizine | Mepyramine | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
537,
24,
849
]
],
[
[
537,
40,
11244
],
[
11244,
1,
849
]
],
[
[
537,
63,
1594
],
[
1594,
24,
849
]
],
[
[
537,
6,
10104
],
[
10104,
45,
849
]
],
[
[
537,
24,
1116
],
[
1116,
63,
849
]
],
[
[
537,
1,
601
],
[
601,
24,
849
]
],
[
[
537,
24,
1190
],
[
1190,
24,
849
]
],
[
[
537,
74,
1376
],
[
1376,
24,
849
]
],
[
[
537,
40,
830
],
[
830,
24,
849
]
],
[
[
537,
62,
685
],
[
685,
24,
849
]
]
] | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Pheniramine"
],
[
"Pheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Cyclizine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
],
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Trimethaphan"
],
[
"Trimethaphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
],
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Cyclizine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nitroglycerin"
],
[
"Nitroglycerin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
]
] | Cyclizine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Mepyramine (Compound)
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Cyclizine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Mepyramine (Compound)
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium and Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Cyclizine (Compound) resembles Trimethaphan (Compound) and Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine and Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Cyclizine (Compound) resembles Diphenhydramine (Compound) and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Cyclizine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Cyclizine may cause a minor interaction that can limit clinical effects when taken with Nitroglycerin and Nitroglycerin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine |
DB00916 | DB12161 | 112 | 730 | [
"DDInter1202",
"DDInter512"
] | Metronidazole | Deutetrabenazine | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections. | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound . This allows less frequent dosing and a lower daily dose with improvement in tolerability . Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine . Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and neuropsychiatric disturbances that interfere with daily functioning and significantly reduce the quality of life. The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions . Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission . Deutetrabenazine depletes the levels of presynaptic dopamine by blocking VMAT2, which is responsible for the uptake of dopamine into synaptic vesicles in monoaminergic neurons and exocytotic release . As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease . In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo . It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. | Minor | 0 | [
[
[
112,
23,
730
]
],
[
[
112,
62,
322
],
[
322,
24,
730
]
],
[
[
112,
23,
1559
],
[
1559,
24,
730
]
],
[
[
112,
24,
770
],
[
770,
24,
730
]
],
[
[
112,
63,
1555
],
[
1555,
24,
730
]
],
[
[
112,
23,
1619
],
[
1619,
63,
730
]
],
[
[
112,
62,
11
],
[
11,
25,
730
]
],
[
[
112,
23,
877
],
[
877,
64,
730
]
],
[
[
112,
24,
1487
],
[
1487,
25,
730
]
],
[
[
112,
23,
1011
],
[
1011,
25,
730
]
]
] | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
]
] | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Deutetrabenazine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Deutetrabenazine
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Deutetrabenazine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Deutetrabenazine |
DB01764 | DB08816 | 805 | 578 | [
"DDInter469",
"DDInter1802"
] | Dalfopristin | Ticagrelor | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Moderate | 1 | [
[
[
805,
24,
578
]
],
[
[
805,
6,
8374
],
[
8374,
45,
578
]
],
[
[
805,
25,
1135
],
[
1135,
62,
578
]
],
[
[
805,
63,
723
],
[
723,
24,
578
]
],
[
[
805,
24,
1297
],
[
1297,
63,
578
]
],
[
[
805,
24,
761
],
[
761,
24,
578
]
],
[
[
805,
62,
1101
],
[
1101,
24,
578
]
],
[
[
805,
25,
313
],
[
313,
63,
578
]
],
[
[
805,
64,
1425
],
[
1425,
24,
578
]
],
[
[
805,
25,
866
],
[
866,
24,
578
]
]
] | [
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Dalfopristin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Dalfopristin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Dalfopristin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Dalfopristin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
],
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Dalfopristin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Dalfopristin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
]
] | Dalfopristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Dalfopristin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Dalfopristin may lead to a major life threatening interaction when taken with Sonidegib and Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Dalfopristin may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Dalfopristin may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor |
DB00910 | DB01045 | 1,041 | 463 | [
"DDInter1394",
"DDInter1590"
] | Paricalcitol | Rifampicin | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | Moderate | 1 | [
[
[
1041,
24,
463
]
],
[
[
1041,
63,
690
],
[
690,
40,
463
]
],
[
[
1041,
6,
8374
],
[
8374,
45,
463
]
],
[
[
1041,
25,
115
],
[
115,
63,
463
]
],
[
[
1041,
24,
1040
],
[
1040,
63,
463
]
],
[
[
1041,
64,
386
],
[
386,
24,
463
]
],
[
[
1041,
75,
1331
],
[
1331,
24,
463
]
],
[
[
1041,
24,
384
],
[
384,
64,
463
]
],
[
[
1041,
63,
690
],
[
690,
1,
1389
],
[
1389,
40,
463
]
],
[
[
1041,
6,
8374
],
[
8374,
45,
690
],
[
690,
40,
463
]
]
] | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} (Compound) resembles {v} (Compound)",
"Rifampicin"
]
],
[
[
"Paricalcitol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rifampicin"
]
],
[
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Paricalcitol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Ergocalciferol"
],
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} (Compound) resembles {v} (Compound)",
"Rifapentine"
],
[
"Rifapentine",
"{u} (Compound) resembles {v} (Compound)",
"Rifampicin"
]
],
[
[
"Paricalcitol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rifabutin"
],
[
"Rifabutin",
"{u} (Compound) resembles {v} (Compound)",
"Rifampicin"
]
]
] | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Paricalcitol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifampicin (Compound)
Paricalcitol may lead to a major life threatening interaction when taken with Aluminum hydroxide and Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Paricalcitol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Paricalcitol (Compound) resembles Ergocalciferol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Rifampicin
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifapentine (Compound) and Rifapentine (Compound) resembles Rifampicin (Compound)
Paricalcitol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifampicin (Compound) |
DB00808 | DB00959 | 1,605 | 1,486 | [
"DDInter916",
"DDInter1191"
] | Indapamide | Methylprednisolone | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly, | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Moderate | 1 | [
[
[
1605,
24,
1486
]
],
[
[
1605,
63,
175
],
[
175,
40,
1486
]
],
[
[
1605,
63,
167
],
[
167,
1,
1486
]
],
[
[
1605,
24,
1220
],
[
1220,
1,
1486
]
],
[
[
1605,
6,
8374
],
[
8374,
45,
1486
]
],
[
[
1605,
21,
28997
],
[
28997,
60,
1486
]
],
[
[
1605,
24,
1674
],
[
1674,
23,
1486
]
],
[
[
1605,
24,
480
],
[
480,
62,
1486
]
],
[
[
1605,
63,
127
],
[
127,
24,
1486
]
],
[
[
1605,
24,
1344
],
[
1344,
63,
1486
]
]
] | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Indapamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Indapamide",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
]
] | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Methylprednisolone (Compound)
Indapamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methylprednisolone (Compound)
Indapamide (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Methylprednisolone (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone |
DB00393 | DB01164 | 854 | 803 | [
"DDInter1295",
"DDInter272"
] | Nimodipine | Calcium chloride | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm. | Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in cement. It can be produced directly from limestone, but large amounts are also produced as a by-product of the Solvay process. Because of its hygroscopic nature, it must be kept in tightly-sealed containers. | Moderate | 1 | [
[
[
854,
24,
803
]
],
[
[
854,
21,
29985
],
[
29985,
60,
803
]
],
[
[
854,
1,
84
],
[
84,
24,
803
]
],
[
[
854,
21,
28809
],
[
28809,
60,
1621
],
[
1621,
40,
803
]
],
[
[
854,
21,
28653
],
[
28653,
60,
504
],
[
504,
24,
803
]
],
[
[
854,
1,
84
],
[
84,
21,
29196
],
[
29196,
60,
803
]
],
[
[
854,
24,
1512
],
[
1512,
24,
1621
],
[
1621,
40,
803
]
],
[
[
854,
21,
28775
],
[
28775,
60,
1453
],
[
1453,
64,
803
]
],
[
[
854,
24,
1512
],
[
1512,
21,
29196
],
[
29196,
60,
803
]
],
[
[
854,
24,
848
],
[
848,
63,
1621
],
[
1621,
40,
803
]
]
] | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium chloride"
]
],
[
[
"Nimodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Vasospasm"
],
[
"Vasospasm",
"{u} (Side Effect) is caused by {v} (Compound)",
"Calcium chloride"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium chloride"
]
],
[
[
"Nimodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} (Compound) resembles {v} (Compound)",
"Calcium chloride"
]
],
[
[
"Nimodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Bradycardia"
],
[
"Bradycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium chloride"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Calcium chloride"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} (Compound) resembles {v} (Compound)",
"Calcium chloride"
]
],
[
[
"Nimodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Phlebitis"
],
[
"Phlebitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ceftriaxone"
],
[
"Ceftriaxone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calcium chloride"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Calcium chloride"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} (Compound) resembles {v} (Compound)",
"Calcium chloride"
]
]
] | Nimodipine (Compound) causes Vasospasm (Side Effect) and Vasospasm (Side Effect) is caused by Calcium chloride (Compound)
Nimodipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium chloride
Nimodipine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Potassium chloride (Compound) and Potassium chloride (Compound) resembles Calcium chloride (Compound)
Nimodipine (Compound) causes Bradycardia (Side Effect) and Bradycardia (Side Effect) is caused by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium chloride
Nimodipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Calcium chloride (Compound)
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Potassium chloride and Potassium chloride (Compound) resembles Calcium chloride (Compound)
Nimodipine (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Ceftriaxone (Compound) and Ceftriaxone may lead to a major life threatening interaction when taken with Calcium chloride
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Calcium chloride (Compound)
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium chloride and Potassium chloride (Compound) resembles Calcium chloride (Compound) |
DB00445 | DB11796 | 322 | 1,612 | [
"DDInter655",
"DDInter786"
] | Epirubicin | Fostemsavir | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the HIV-1 viral lifecycle. The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically orthogonal therapies) for the treatment of HIV-1 patients with resistant infections. Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant HIV-1 infection whom are failing their current therapy.[L14867,L14917] Targeting gp120 subunits is a new and novel therapeutic approach to HIV-1 infection, and the addition of attachment inhibitors, like temsavir, to the armament of therapies targeted against HIV-1 fills a necessary niche for therapeutic options in patients left with few, if any, viable treatments. | Moderate | 1 | [
[
[
322,
24,
1612
]
],
[
[
322,
24,
1476
],
[
1476,
62,
1612
]
],
[
[
322,
63,
1101
],
[
1101,
23,
1612
]
],
[
[
322,
23,
112
],
[
112,
23,
1612
]
],
[
[
322,
24,
1424
],
[
1424,
24,
1612
]
],
[
[
322,
24,
823
],
[
823,
63,
1612
]
],
[
[
322,
63,
1010
],
[
1010,
24,
1612
]
],
[
[
322,
35,
51
],
[
51,
24,
1612
]
],
[
[
322,
25,
770
],
[
770,
24,
1612
]
],
[
[
322,
64,
1064
],
[
1064,
24,
1612
]
]
] | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Epirubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
]
] | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Epirubicin (Compound) resembles Daunorubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Epirubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Epirubicin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir |
DB00860 | DB11095 | 891 | 235 | [
"DDInter1513",
"DDInter505"
] | Prednisolone | Desirudin | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52. It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing. | Major | 2 | [
[
[
891,
25,
235
]
],
[
[
891,
24,
1004
],
[
1004,
24,
235
]
],
[
[
891,
62,
1461
],
[
1461,
24,
235
]
],
[
[
891,
63,
529
],
[
529,
24,
235
]
],
[
[
891,
24,
972
],
[
972,
63,
235
]
],
[
[
891,
63,
59
],
[
59,
25,
235
]
],
[
[
891,
1,
175
],
[
175,
25,
235
]
],
[
[
891,
24,
1479
],
[
1479,
25,
235
]
],
[
[
891,
24,
283
],
[
283,
64,
235
]
],
[
[
891,
62,
1018
],
[
1018,
25,
235
]
]
] | [
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
],
[
"Choline salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
],
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
]
] | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicylate may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Etodolac and Etodolac may lead to a major life threatening interaction when taken with Desirudin
Prednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may lead to a major life threatening interaction when taken with Desirudin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Desirudin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Desirudin
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Desirudin |
DB00281 | DB06448 | 608 | 171 | [
"DDInter1066",
"DDInter1087"
] | Lidocaine | Lonafarnib | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.[A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] | Moderate | 1 | [
[
[
608,
24,
171
]
],
[
[
608,
23,
1051
],
[
1051,
24,
171
]
],
[
[
608,
24,
1010
],
[
1010,
24,
171
]
],
[
[
608,
23,
98
],
[
98,
63,
171
]
],
[
[
608,
62,
1324
],
[
1324,
24,
171
]
],
[
[
608,
23,
129
],
[
129,
64,
171
]
],
[
[
608,
24,
723
],
[
723,
25,
171
]
],
[
[
608,
24,
1619
],
[
1619,
64,
171
]
],
[
[
608,
63,
966
],
[
966,
25,
171
]
],
[
[
608,
23,
1220
],
[
1220,
25,
171
]
]
] | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
]
] | Lidocaine may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lonafarnib
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Lonafarnib
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Lonafarnib
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide may lead to a major life threatening interaction when taken with Lonafarnib
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lonafarnib |
DB00572 | DB08938 | 85 | 1,384 | [
"DDInter136",
"DDInter1112"
] | Atropine | Magaldrate | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products.[A251660,L42840] Atropine is a competitive, reversible antagonist of muscarinic receptors that blocks the effects of acetylcholine and other choline esters.[A251660,L42815,L42825,L42835] It has a variety of therapeutic applications, including pupil dilation and the treatment of anticholinergic poisoning and symptomatic bradycardia in the absence of reversible causes. Atropine is a relatively inexpensive drug and | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
85,
24,
1384
]
],
[
[
85,
24,
1178
],
[
1178,
23,
1384
]
],
[
[
85,
63,
461
],
[
461,
23,
1384
]
],
[
[
85,
62,
1252
],
[
1252,
23,
1384
]
],
[
[
85,
24,
1123
],
[
1123,
24,
1384
]
],
[
[
85,
24,
1178
],
[
1178,
63,
167
],
[
167,
23,
1384
]
],
[
[
85,
63,
461
],
[
461,
24,
167
],
[
167,
23,
1384
]
],
[
[
85,
24,
684
],
[
684,
24,
167
],
[
167,
23,
1384
]
],
[
[
85,
24,
1630
],
[
1630,
1,
1178
],
[
1178,
23,
1384
]
],
[
[
85,
62,
1252
],
[
1252,
24,
167
],
[
167,
23,
1384
]
]
] | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
]
] | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Atropine may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Atropine may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate |
DB00533 | DB09054 | 1,416 | 384 | [
"DDInter1613",
"DDInter905"
] | Rofecoxib | Idelalisib | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2 | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
1416,
24,
384
]
],
[
[
1416,
63,
305
],
[
305,
24,
384
]
],
[
[
1416,
24,
891
],
[
891,
24,
384
]
],
[
[
1416,
24,
1613
],
[
1613,
63,
384
]
],
[
[
1416,
24,
1486
],
[
1486,
25,
384
]
],
[
[
1416,
25,
629
],
[
629,
25,
384
]
],
[
[
1416,
24,
1019
],
[
1019,
64,
384
]
],
[
[
1416,
63,
305
],
[
305,
24,
1627
],
[
1627,
62,
384
]
],
[
[
1416,
24,
891
],
[
891,
24,
555
],
[
555,
23,
384
]
],
[
[
1416,
63,
1555
],
[
1555,
25,
318
],
[
318,
23,
384
]
]
] | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Rofecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
]
] | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may lead to a major life threatening interaction when taken with Idelalisib
Rofecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Idelalisib
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Idelalisib
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib |
DB00703 | DB11057 | 997 | 720 | [
"DDInter1167",
"DDInter1223"
] | Methazolamide | Mineral oil | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced by solvent extraction, catalytic hydrotreating, or hydrocracking. Unrefined or mildly treated mineral oils are classified as Group 3 carcinogens by the World Health Organizations, as chronic exposure to these aromatics including alkylated polycyclic aromatic compounds (PAC) can lead to skin cancer. Mineral oil is a common ingredient in baby lotions, cold creams, ointments and cosmetics to treat and prevent dry, rough, scaly, itchy skin and minor skin irritations. It is also used as a mild laxative for human or veterinary uses. | Moderate | 1 | [
[
[
997,
24,
720
]
],
[
[
997,
63,
175
],
[
175,
24,
720
]
],
[
[
997,
24,
1486
],
[
1486,
24,
720
]
],
[
[
997,
64,
1425
],
[
1425,
24,
720
]
],
[
[
997,
40,
471
],
[
471,
24,
720
]
],
[
[
997,
25,
57
],
[
57,
24,
720
]
],
[
[
997,
24,
1019
],
[
1019,
63,
720
]
],
[
[
997,
63,
175
],
[
175,
63,
323
],
[
323,
24,
720
]
],
[
[
997,
24,
1486
],
[
1486,
1,
175
],
[
175,
24,
720
]
],
[
[
997,
64,
1425
],
[
1425,
25,
927
],
[
927,
63,
720
]
]
] | [
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Methazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Methazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Methazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Methazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
]
] | Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Methazolamide may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Methazolamide (Compound) resembles Acetazolamide (Compound) and Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Methazolamide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Methazolamide may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil |
DB08931 | DB11979 | 947 | 1,320 | [
"DDInter1600",
"DDInter625"
] | Riociguat | Elagolix | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III. Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. | Moderate | 1 | [
[
[
947,
24,
1320
]
],
[
[
947,
63,
129
],
[
129,
24,
1320
]
],
[
[
947,
24,
913
],
[
913,
24,
1320
]
],
[
[
947,
24,
484
],
[
484,
63,
1320
]
],
[
[
947,
25,
760
],
[
760,
25,
1320
]
],
[
[
947,
24,
384
],
[
384,
25,
1320
]
],
[
[
947,
63,
609
],
[
609,
25,
1320
]
],
[
[
947,
63,
129
],
[
129,
64,
168
],
[
168,
23,
1320
]
],
[
[
947,
24,
913
],
[
913,
64,
168
],
[
168,
23,
1320
]
],
[
[
947,
24,
484
],
[
484,
62,
271
],
[
271,
23,
1320
]
]
] | [
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Riociguat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Elagolix"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Elagolix"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Elagolix"
]
]
] | Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Riociguat may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Elagolix
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Elagolix
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Elagolix
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Elagolix |
DB00277 | DB00598 | 1,031 | 1,523 | [
"DDInter1791",
"DDInter1013"
] | Theophylline | Labetalol | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Major | 2 | [
[
[
1031,
25,
1523
]
],
[
[
1031,
24,
455
],
[
455,
64,
1523
]
],
[
[
1031,
24,
1148
],
[
1148,
63,
1523
]
],
[
[
1031,
24,
1052
],
[
1052,
1,
1523
]
],
[
[
1031,
6,
12523
],
[
12523,
45,
1523
]
],
[
[
1031,
21,
28876
],
[
28876,
60,
1523
]
],
[
[
1031,
24,
1152
],
[
1152,
23,
1523
]
],
[
[
1031,
23,
417
],
[
417,
23,
1523
]
],
[
[
1031,
24,
752
],
[
752,
24,
1523
]
],
[
[
1031,
25,
497
],
[
497,
63,
1523
]
]
] | [
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Labetalol"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Labetalol"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} (Compound) resembles {v} (Compound)",
"Labetalol"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Labetalol"
]
],
[
[
"Theophylline",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactoid reaction"
],
[
"Anaphylactoid reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Labetalol"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Labetalol"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Labetalol"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
]
] | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Labetalol
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine (Compound) resembles Labetalol (Compound)
Theophylline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Labetalol (Compound)
Theophylline (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect) is caused by Labetalol (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a minor interaction that can limit clinical effects when taken with Labetalol
Theophylline may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Labetalol
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Theophylline may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Labetalol |
DB00261 | DB06209 | 702 | 256 | [
"DDInter93",
"DDInter1508"
] | Anagrelide | Prasugrel | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009. | Major | 2 | [
[
[
702,
25,
256
]
],
[
[
702,
21,
28792
],
[
28792,
60,
256
]
],
[
[
702,
23,
944
],
[
944,
62,
256
]
],
[
[
702,
24,
752
],
[
752,
23,
256
]
],
[
[
702,
25,
419
],
[
419,
23,
256
]
],
[
[
702,
24,
901
],
[
901,
24,
256
]
],
[
[
702,
24,
1427
],
[
1427,
63,
256
]
],
[
[
702,
63,
529
],
[
529,
24,
256
]
],
[
[
702,
25,
1237
],
[
1237,
24,
256
]
],
[
[
702,
64,
1230
],
[
1230,
24,
256
]
]
] | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prasugrel"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halothane"
],
[
"Halothane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
]
] | Anagrelide (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Prasugrel (Compound)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Anagrelide may lead to a major life threatening interaction when taken with Halothane and Halothane may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Anagrelide may lead to a major life threatening interaction when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Anagrelide may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel |
DB00258 | DB00562 | 666 | 1,014 | [
"DDInter270",
"DDInter188"
] | Calcium acetate | Benzthiazide | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. | Moderate | 1 | [
[
[
666,
24,
1014
]
],
[
[
666,
24,
811
],
[
811,
40,
1014
]
],
[
[
666,
24,
674
],
[
674,
1,
1014
]
],
[
[
666,
24,
1572
],
[
1572,
62,
1014
]
],
[
[
666,
63,
964
],
[
964,
23,
1014
]
],
[
[
666,
24,
811
],
[
811,
40,
11374
],
[
11374,
1,
1014
]
],
[
[
666,
24,
674
],
[
674,
1,
323
],
[
323,
40,
1014
]
],
[
[
666,
24,
359
],
[
359,
40,
811
],
[
811,
40,
1014
]
],
[
[
666,
24,
504
],
[
504,
1,
674
],
[
674,
1,
1014
]
],
[
[
666,
24,
1572
],
[
1572,
62,
811
],
[
811,
40,
1014
]
]
] | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Methyclothiazide"
],
[
"Methyclothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
]
]
] | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Benzthiazide (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Benzthiazide (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Methyclothiazide (Compound) and Methyclothiazide (Compound) resembles Benzthiazide (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Bendroflumethiazide (Compound) and Bendroflumethiazide (Compound) resembles Benzthiazide (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Metolazone (Compound) and Metolazone (Compound) resembles Benzthiazide (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide (Compound) resembles Benzthiazide (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Metolazone and Metolazone (Compound) resembles Benzthiazide (Compound) |
DB05239 | DB11828 | 866 | 1,406 | [
"DDInter425",
"DDInter1281"
] | Cobimetinib | Neratinib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
866,
24,
1406
]
],
[
[
866,
63,
392
],
[
392,
24,
1406
]
],
[
[
866,
25,
1510
],
[
1510,
24,
1406
]
],
[
[
866,
24,
850
],
[
850,
24,
1406
]
],
[
[
866,
24,
1619
],
[
1619,
63,
1406
]
],
[
[
866,
25,
1593
],
[
1593,
25,
1406
]
],
[
[
866,
25,
283
],
[
283,
64,
1406
]
],
[
[
866,
64,
609
],
[
609,
25,
1406
]
],
[
[
866,
63,
529
],
[
529,
25,
1406
]
],
[
[
866,
63,
392
],
[
392,
23,
1135
],
[
1135,
23,
1406
]
]
] | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Neratinib"
]
]
] | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Cobimetinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Cobimetinib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Neratinib
Cobimetinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Neratinib
Cobimetinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Neratinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may lead to a major life threatening interaction when taken with Neratinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib |
DB00451 | DB00489 | 542 | 17 | [
"DDInter1064",
"DDInter1704"
] | Levothyroxine | Sotalol | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T<sub>4</sub> (tetraiodothyronine or thyroxine) and T<sub>3</sub> (triiodothyronine or ), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.[F4636,A35722] In response to Thyroid Stimulating Hormone (TSH) release by | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376] | Minor | 0 | [
[
[
542,
23,
17
]
],
[
[
542,
62,
88
],
[
88,
40,
17
]
],
[
[
542,
21,
29648
],
[
29648,
60,
17
]
],
[
[
542,
62,
417
],
[
417,
23,
17
]
],
[
[
542,
24,
115
],
[
115,
62,
17
]
],
[
[
542,
40,
1152
],
[
1152,
23,
17
]
],
[
[
542,
24,
1296
],
[
1296,
63,
17
]
],
[
[
542,
63,
1685
],
[
1685,
24,
17
]
],
[
[
542,
23,
752
],
[
752,
63,
17
]
],
[
[
542,
24,
913
],
[
913,
64,
17
]
]
] | [
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sotalol"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Sotalol"
]
],
[
[
"Levothyroxine",
"{u} (Compound) causes {v} (Side Effect)",
"Disorientation"
],
[
"Disorientation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sotalol"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sotalol"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sotalol"
]
],
[
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sotalol"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
]
] | Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol (Compound) resembles Sotalol (Compound)
Levothyroxine (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Sotalol (Compound)
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Sotalol
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Sotalol
Levothyroxine (Compound) resembles Liothyronine (Compound) and Liothyronine may cause a minor interaction that can limit clinical effects when taken with Sotalol
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Sotalol |
DB00404 | DB00405 | 523 | 128 | [
"DDInter54",
"DDInter517"
] | Alprazolam | Dexbrompheniramine | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981. | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
523,
24,
128
]
],
[
[
523,
24,
662
],
[
662,
63,
128
]
],
[
[
523,
1,
686
],
[
686,
63,
128
]
],
[
[
523,
1,
902
],
[
902,
24,
128
]
],
[
[
523,
40,
1382
],
[
1382,
63,
128
]
],
[
[
523,
64,
475
],
[
475,
24,
128
]
],
[
[
523,
40,
1174
],
[
1174,
24,
128
]
],
[
[
523,
63,
701
],
[
701,
24,
128
]
],
[
[
523,
63,
1594
],
[
1594,
35,
128
]
],
[
[
523,
24,
662
],
[
662,
35,
1376
],
[
1376,
63,
128
]
]
] | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Oxazepam"
],
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
],
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Alprazolam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Temazepam"
],
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
]
] | Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Alprazolam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Alprazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Alprazolam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Alprazolam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Alprazolam (Compound) resembles Temazepam (Compound) and Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Diphenhydramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine |
DB00081 | DB06643 | 273 | 1,136 | [
"DDInter1838",
"DDInter500"
] | Tositumomab | Denosumab | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012. | Moderate | 1 | [
[
[
273,
24,
1136
]
],
[
[
273,
25,
1213
],
[
1213,
24,
1136
]
],
[
[
273,
25,
1510
],
[
1510,
63,
1136
]
],
[
[
273,
24,
270
],
[
270,
63,
1136
]
],
[
[
273,
24,
58
],
[
58,
24,
1136
]
],
[
[
273,
64,
1172
],
[
1172,
24,
1136
]
],
[
[
273,
63,
1184
],
[
1184,
24,
1136
]
],
[
[
273,
25,
1064
],
[
1064,
25,
1136
]
],
[
[
273,
25,
1213
],
[
1213,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
273,
25,
1377
],
[
1377,
25,
1213
],
[
1213,
24,
1136
]
]
] | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Denosumab"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
]
] | Tositumomab may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Tositumomab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Tositumomab may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Tositumomab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Denosumab
Tositumomab may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Tositumomab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab |
DB10276 | DB11569 | 1,624 | 1,093 | [
"DDInter1623",
"DDInter1003"
] | Rotavirus vaccine | Ixekizumab | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection. | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. | Major | 2 | [
[
[
1624,
25,
1093
]
],
[
[
1624,
64,
66
],
[
66,
24,
1093
]
],
[
[
1624,
25,
270
],
[
270,
63,
1093
]
],
[
[
1624,
64,
1057
],
[
1057,
25,
1093
]
],
[
[
1624,
25,
676
],
[
676,
64,
1093
]
],
[
[
1624,
64,
66
],
[
66,
23,
1114
],
[
1114,
23,
1093
]
],
[
[
1624,
64,
134
],
[
134,
63,
1461
],
[
1461,
23,
1093
]
],
[
[
1624,
64,
599
],
[
599,
24,
66
],
[
66,
24,
1093
]
],
[
[
1624,
64,
4
],
[
4,
63,
66
],
[
66,
24,
1093
]
],
[
[
1624,
25,
270
],
[
270,
62,
1114
],
[
1114,
23,
1093
]
]
] | [
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
]
] | Rotavirus vaccine may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Rotavirus vaccine may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Rotavirus vaccine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ixekizumab
Rotavirus vaccine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ixekizumab
Rotavirus vaccine may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Rotavirus vaccine may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Rotavirus vaccine may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Rotavirus vaccine may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Rotavirus vaccine may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ixekizumab |
DB06779 | DB11095 | 365 | 235 | [
"DDInter470",
"DDInter505"
] | Dalteparin | Desirudin | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52. It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing. | Major | 2 | [
[
[
365,
25,
235
]
],
[
[
365,
23,
297
],
[
297,
23,
235
]
],
[
[
365,
63,
1100
],
[
1100,
24,
235
]
],
[
[
365,
24,
1004
],
[
1004,
24,
235
]
],
[
[
365,
24,
321
],
[
321,
63,
235
]
],
[
[
365,
25,
578
],
[
578,
24,
235
]
],
[
[
365,
64,
885
],
[
885,
24,
235
]
],
[
[
365,
64,
1409
],
[
1409,
25,
235
]
],
[
[
365,
25,
1421
],
[
1421,
64,
235
]
],
[
[
365,
25,
1618
],
[
1618,
25,
235
]
]
] | [
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Dalteparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Desirudin"
]
],
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
],
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
]
] | Dalteparin may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Desirudin
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Dalteparin may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Dalteparin may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Dalteparin may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Desirudin
Dalteparin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Desirudin
Dalteparin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Desirudin |
DB00762 | DB01337 | 613 | 1,579 | [
"DDInter973",
"DDInter1385"
] | Irinotecan | Pancuronium | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde). | A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release. | Minor | 0 | [
[
[
613,
23,
1579
]
],
[
[
613,
62,
1610
],
[
1610,
1,
1579
]
],
[
[
613,
23,
728
],
[
728,
1,
1579
]
],
[
[
613,
6,
10558
],
[
10558,
45,
1579
]
],
[
[
613,
7,
4456
],
[
4456,
46,
1579
]
],
[
[
613,
18,
2183
],
[
2183,
57,
1579
]
],
[
[
613,
21,
28717
],
[
28717,
60,
1579
]
],
[
[
613,
63,
544
],
[
544,
24,
1579
]
],
[
[
613,
24,
1220
],
[
1220,
24,
1579
]
],
[
[
613,
62,
1610
],
[
1610,
1,
1665
],
[
1665,
1,
1579
]
]
] | [
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pancuronium"
]
],
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rocuronium"
],
[
"Rocuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pancuronium"
]
],
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vecuronium"
],
[
"Vecuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pancuronium"
]
],
[
[
"Irinotecan",
"{u} (Compound) binds {v} (Gene)",
"BCHE"
],
[
"BCHE",
"{u} (Gene) is bound by {v} (Compound)",
"Pancuronium"
]
],
[
[
"Irinotecan",
"{u} (Compound) upregulates {v} (Gene)",
"NOTCH1"
],
[
"NOTCH1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Pancuronium"
]
],
[
[
"Irinotecan",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Pancuronium"
]
],
[
[
"Irinotecan",
"{u} (Compound) causes {v} (Side Effect)",
"Flushing"
],
[
"Flushing",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pancuronium"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
]
],
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rocuronium"
],
[
"Rocuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pipecuronium"
],
[
"Pipecuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pancuronium"
]
]
] | Irinotecan may cause a minor interaction that can limit clinical effects when taken with Rocuronium and Rocuronium (Compound) resembles Pancuronium (Compound)
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Vecuronium and Vecuronium (Compound) resembles Pancuronium (Compound)
Irinotecan (Compound) binds BCHE (Gene) and BCHE (Gene) is bound by Pancuronium (Compound)
Irinotecan (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is upregulated by Pancuronium (Compound)
Irinotecan (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Pancuronium (Compound)
Irinotecan (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Pancuronium (Compound)
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Rocuronium and Rocuronium (Compound) resembles Pipecuronium (Compound) and Pipecuronium (Compound) resembles Pancuronium (Compound) |
DB00250 | DB00727 | 10 | 685 | [
"DDInter475",
"DDInter1304"
] | Dapsone | Nitroglycerin | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) | Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate and a vasodilating agent that was first discovered in 1847. Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced headaches in factory workers while workers with angina pectoris or heart failure experienced relief from chest pain.[A180166,A180172] Its use as a treatment for angina dates back to 1879 and is still used to treat and prevent angina. Nitroglycerin causes vasodilation in both arteries and veins. Nitroglycerin is used in a variety of different conditions, including angina pectoris due to coronary artery disease,[L7102,L7141,L38369,L42320] peri-operative hypertension, congestive heart failure, and chronic anal fissure. It is also used to induce intraoperative hypotension. | Moderate | 1 | [
[
[
10,
24,
685
]
],
[
[
10,
21,
29966
],
[
29966,
60,
685
]
],
[
[
10,
25,
1455
],
[
1455,
64,
685
]
],
[
[
10,
21,
29966
],
[
29966,
60,
1264
],
[
1264,
63,
685
]
],
[
[
10,
21,
28722
],
[
28722,
60,
85
],
[
85,
23,
685
]
],
[
[
10,
21,
29247
],
[
29247,
60,
1442
],
[
1442,
62,
685
]
],
[
[
10,
24,
1107
],
[
1107,
6,
6158
],
[
6158,
45,
685
]
],
[
[
10,
25,
1455
],
[
1455,
63,
1450
],
[
1450,
63,
685
]
],
[
[
10,
25,
1455
],
[
1455,
24,
433
],
[
433,
63,
685
]
],
[
[
10,
24,
467
],
[
467,
5,
11576
],
[
11576,
49,
685
]
]
] | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitroglycerin"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Application site reaction"
],
[
"Application site reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nitroglycerin"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitroglycerin"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Application site reaction"
],
[
"Application site reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitroglycerin"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atropine"
],
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nitroglycerin"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Pharyngitis"
],
[
"Pharyngitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nitroglycerin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isosorbide mononitrate"
],
[
"Isosorbide mononitrate",
"{u} (Compound) binds {v} (Gene)",
"GUCY1B3"
],
[
"GUCY1B3",
"{u} (Gene) is bound by {v} (Compound)",
"Nitroglycerin"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitroglycerin"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitroglycerin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} (Compound) treats {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is palliated by {v} (Compound)",
"Nitroglycerin"
]
]
] | Dapsone (Compound) causes Application site reaction (Side Effect) and Application site reaction (Side Effect) is caused by Nitroglycerin (Compound)
Dapsone may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Nitroglycerin
Dapsone (Compound) causes Application site reaction (Side Effect) and Application site reaction (Side Effect) is caused by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Nitroglycerin
Dapsone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Atropine (Compound) and Atropine may cause a minor interaction that can limit clinical effects when taken with Nitroglycerin
Dapsone (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Scopolamine (Compound) and Scopolamine may cause a minor interaction that can limit clinical effects when taken with Nitroglycerin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Isosorbide mononitrate and Isosorbide mononitrate (Compound) binds GUCY1B3 (Gene) and GUCY1B3 (Gene) is bound by Nitroglycerin (Compound)
Dapsone may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitroglycerin
Dapsone may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitroglycerin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is palliated by Nitroglycerin (Compound) |
DB00405 | DB01403 | 128 | 9 | [
"DDInter517",
"DDInter1175"
] | Dexbrompheniramine | Methotrimeprazine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
128,
24,
9
]
],
[
[
128,
24,
1178
],
[
1178,
40,
9
]
],
[
[
128,
24,
1164
],
[
1164,
1,
9
]
],
[
[
128,
24,
401
],
[
401,
24,
9
]
],
[
[
128,
6,
10104
],
[
10104,
45,
9
]
],
[
[
128,
24,
407
],
[
407,
63,
9
]
],
[
[
128,
63,
352
],
[
352,
24,
9
]
],
[
[
128,
74,
1594
],
[
1594,
24,
9
]
],
[
[
128,
40,
28
],
[
28,
63,
9
]
],
[
[
128,
25,
1621
],
[
1621,
25,
9
]
]
] | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrimeprazine"
]
]
] | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Methotrimeprazine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Dexbrompheniramine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Methotrimeprazine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Dexbrompheniramine (Compound) resembles Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Dexbrompheniramine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Methotrimeprazine |
DB01181 | DB01224 | 1,532 | 623 | [
"DDInter906",
"DDInter1553"
] | Ifosfamide | Quetiapine | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine]. | Moderate | 1 | [
[
[
1532,
24,
623
]
],
[
[
1532,
63,
827
],
[
827,
1,
623
]
],
[
[
1532,
64,
695
],
[
695,
1,
623
]
],
[
[
1532,
6,
6799
],
[
6799,
45,
623
]
],
[
[
1532,
7,
8953
],
[
8953,
46,
623
]
],
[
[
1532,
18,
17480
],
[
17480,
57,
623
]
],
[
[
1532,
21,
29356
],
[
29356,
60,
623
]
],
[
[
1532,
63,
1376
],
[
1376,
24,
623
]
],
[
[
1532,
24,
214
],
[
214,
63,
623
]
],
[
[
1532,
64,
770
],
[
770,
24,
623
]
]
] | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
]
],
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
]
],
[
[
"Ifosfamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Ifosfamide",
"{u} (Compound) upregulates {v} (Gene)",
"NNT"
],
[
"NNT",
"{u} (Gene) is upregulated by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Ifosfamide",
"{u} (Compound) downregulates {v} (Gene)",
"ENOPH1"
],
[
"ENOPH1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Ifosfamide",
"{u} (Compound) causes {v} (Side Effect)",
"Salivary hypersecretion"
],
[
"Salivary hypersecretion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
]
] | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Ifosfamide may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Ifosfamide (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Quetiapine (Compound)
Ifosfamide (Compound) upregulates NNT (Gene) and NNT (Gene) is upregulated by Quetiapine (Compound)
Ifosfamide (Compound) downregulates ENOPH1 (Gene) and ENOPH1 (Gene) is downregulated by Quetiapine (Compound)
Ifosfamide (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Quetiapine (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Ifosfamide may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine |
DB00563 | DB12001 | 663 | 564 | [
"DDInter1174",
"DDInter7"
] | Methotrexate | Abemaciclib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with . Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. | Moderate | 1 | [
[
[
663,
24,
564
]
],
[
[
663,
24,
868
],
[
868,
24,
564
]
],
[
[
663,
63,
58
],
[
58,
24,
564
]
],
[
[
663,
25,
1249
],
[
1249,
24,
564
]
],
[
[
663,
24,
242
],
[
242,
63,
564
]
],
[
[
663,
24,
68
],
[
68,
64,
564
]
],
[
[
663,
25,
1011
],
[
1011,
25,
564
]
],
[
[
663,
24,
913
],
[
913,
25,
564
]
],
[
[
663,
64,
581
],
[
581,
25,
564
]
],
[
[
663,
25,
779
],
[
779,
64,
564
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
],
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Methotrexate may lead to a major life threatening interaction when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and Troleandomycin may lead to a major life threatening interaction when taken with Abemaciclib
Methotrexate may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Abemaciclib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Abemaciclib
Methotrexate may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Abemaciclib
Methotrexate may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Abemaciclib |
DB00641 | DB01241 | 467 | 1,206 | [
"DDInter1675",
"DDInter812"
] | Simvastatin | Gemfibrozil | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a | Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. Gemfibrozil was granted FDA approval on 21 December 1981. | Major | 2 | [
[
[
467,
25,
1206
]
],
[
[
467,
5,
11576
],
[
11576,
44,
1206
]
],
[
[
467,
6,
8374
],
[
8374,
45,
1206
]
],
[
[
467,
7,
2473
],
[
2473,
46,
1206
]
],
[
[
467,
18,
3586
],
[
3586,
46,
1206
]
],
[
[
467,
18,
6797
],
[
6797,
57,
1206
]
],
[
[
467,
21,
29232
],
[
29232,
60,
1206
]
],
[
[
467,
24,
1476
],
[
1476,
62,
1206
]
],
[
[
467,
24,
129
],
[
129,
63,
1206
]
],
[
[
467,
63,
663
],
[
663,
24,
1206
]
]
] | [
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemfibrozil"
]
],
[
[
"Simvastatin",
"{u} (Compound) treats {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is treated by {v} (Compound)",
"Gemfibrozil"
]
],
[
[
"Simvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Gemfibrozil"
]
],
[
[
"Simvastatin",
"{u} (Compound) upregulates {v} (Gene)",
"RHOA"
],
[
"RHOA",
"{u} (Gene) is upregulated by {v} (Compound)",
"Gemfibrozil"
]
],
[
[
"Simvastatin",
"{u} (Compound) downregulates {v} (Gene)",
"EZH2"
],
[
"EZH2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Gemfibrozil"
]
],
[
[
"Simvastatin",
"{u} (Compound) downregulates {v} (Gene)",
"CYCS"
],
[
"CYCS",
"{u} (Gene) is downregulated by {v} (Compound)",
"Gemfibrozil"
]
],
[
[
"Simvastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gemfibrozil"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemfibrozil"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
]
]
] | Simvastatin (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Gemfibrozil (Compound)
Simvastatin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gemfibrozil (Compound)
Simvastatin (Compound) upregulates RHOA (Gene) and RHOA (Gene) is upregulated by Gemfibrozil (Compound)
Simvastatin (Compound) downregulates EZH2 (Gene) and EZH2 (Gene) is upregulated by Gemfibrozil (Compound)
Simvastatin (Compound) downregulates CYCS (Gene) and CYCS (Gene) is downregulated by Gemfibrozil (Compound)
Simvastatin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Gemfibrozil (Compound)
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Gemfibrozil
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil |
DB00758 | DB15233 | 1,347 | 1,650 | [
"DDInter413",
"DDInter142"
] | Clopidogrel | Avapritinib | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 and EMA approval on 24 September 2020. | Major | 2 | [
[
[
1347,
25,
1650
]
],
[
[
1347,
62,
522
],
[
522,
24,
1650
]
],
[
[
1347,
24,
557
],
[
557,
24,
1650
]
],
[
[
1347,
63,
121
],
[
121,
24,
1650
]
],
[
[
1347,
63,
1512
],
[
1512,
25,
1650
]
],
[
[
1347,
24,
848
],
[
848,
25,
1650
]
],
[
[
1347,
25,
4
],
[
4,
25,
1650
]
],
[
[
1347,
64,
1578
],
[
1578,
25,
1650
]
],
[
[
1347,
36,
256
],
[
256,
25,
1650
]
],
[
[
1347,
63,
1274
],
[
1274,
37,
1650
]
]
] | [
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Clopidogrel",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
]
] | Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Avapritinib
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Avapritinib
Clopidogrel may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Avapritinib
Clopidogrel may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Avapritinib
Clopidogrel (Compound) resembles Prasugrel (Compound) and Clopidogrel may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Avapritinib
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib and Flurbiprofen may lead to a major life threatening interaction when taken with Avapritinib |
DB01394 | DB04845 | 1,554 | 309 | [
"DDInter431",
"DDInter1001"
] | Colchicine | Ixabepilone | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammatory and fibrotic conditions. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Moderate | 1 | [
[
[
1554,
24,
309
]
],
[
[
1554,
6,
8374
],
[
8374,
45,
309
]
],
[
[
1554,
7,
16974
],
[
16974,
45,
309
]
],
[
[
1554,
21,
28736
],
[
28736,
60,
309
]
],
[
[
1554,
64,
1419
],
[
1419,
24,
309
]
],
[
[
1554,
24,
1434
],
[
1434,
63,
309
]
],
[
[
1554,
25,
1593
],
[
1593,
63,
309
]
],
[
[
1554,
24,
1487
],
[
1487,
24,
309
]
],
[
[
1554,
63,
1213
],
[
1213,
24,
309
]
],
[
[
1554,
63,
1057
],
[
1057,
25,
309
]
]
] | [
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Colchicine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Colchicine",
"{u} (Compound) upregulates {v} (Gene)",
"TUBB6"
],
[
"TUBB6",
"{u} (Gene) is bound by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Colchicine",
"{u} (Compound) causes {v} (Side Effect)",
"Dehydration"
],
[
"Dehydration",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
],
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixabepilone"
]
]
] | Colchicine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Colchicine (Compound) upregulates TUBB6 (Gene) and TUBB6 (Gene) is bound by Ixabepilone (Compound)
Colchicine (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compound)
Colchicine may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Colchicine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ixabepilone |
DB01268 | DB04946 | 1,151 | 924 | [
"DDInter1731",
"DDInter907"
] | Sunitinib | Iloperidone | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009. | Major | 2 | [
[
[
1151,
25,
924
]
],
[
[
1151,
63,
1664
],
[
1664,
1,
924
]
],
[
[
1151,
64,
1425
],
[
1425,
25,
924
]
],
[
[
1151,
63,
519
],
[
519,
40,
924
]
],
[
[
1151,
6,
21998
],
[
21998,
45,
924
]
],
[
[
1151,
21,
28809
],
[
28809,
60,
924
]
],
[
[
1151,
62,
112
],
[
112,
23,
924
]
],
[
[
1151,
24,
214
],
[
214,
63,
924
]
],
[
[
1151,
63,
1324
],
[
1324,
24,
924
]
],
[
[
1151,
24,
1254
],
[
1254,
24,
924
]
]
] | [
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} (Compound) resembles {v} (Compound)",
"Iloperidone"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} (Compound) resembles {v} (Compound)",
"Iloperidone"
]
],
[
[
"Sunitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v} (Compound)",
"Iloperidone"
]
],
[
[
"Sunitinib",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iloperidone"
]
],
[
[
"Sunitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iloperidone"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
]
] | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Sunitinib may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Iloperidone
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (Compound)
Sunitinib (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Iloperidone (Compound)
Sunitinib (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Iloperidone (Compound)
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Iloperidone
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone |
DB00903 | DB01001 | 1,680 | 688 | [
"DDInter686",
"DDInter1632"
] | Etacrynic acid | Salbutamol | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic. | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.[Label,A174379,A174400] | Moderate | 1 | [
[
[
1680,
24,
688
]
],
[
[
1680,
24,
455
],
[
455,
24,
688
]
],
[
[
1680,
21,
28714
],
[
28714,
60,
688
]
],
[
[
1680,
24,
1220
],
[
1220,
62,
688
]
],
[
[
1680,
63,
870
],
[
870,
23,
688
]
],
[
[
1680,
24,
1486
],
[
1486,
23,
688
]
],
[
[
1680,
24,
286
],
[
286,
63,
688
]
],
[
[
1680,
63,
176
],
[
176,
24,
688
]
],
[
[
1680,
64,
1166
],
[
1166,
24,
688
]
],
[
[
1680,
25,
57
],
[
57,
63,
688
]
]
] | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Etacrynic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salbutamol"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Etacrynic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Etacrynic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
]
] | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Etacrynic acid (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Salbutamol (Compound)
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Salbutamol
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Salbutamol
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Salbutamol
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Etacrynic acid may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Etacrynic acid may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol |
DB06791 | DB09073 | 1,446 | 951 | [
"DDInter1021",
"DDInter1379"
] | Lanreotide | Palbociclib | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy. | Moderate | 1 | [
[
[
1446,
24,
951
]
],
[
[
1446,
23,
907
],
[
907,
62,
951
]
],
[
[
1446,
24,
159
],
[
159,
63,
951
]
],
[
[
1446,
63,
761
],
[
761,
24,
951
]
],
[
[
1446,
24,
154
],
[
154,
24,
951
]
],
[
[
1446,
24,
676
],
[
676,
64,
951
]
],
[
[
1446,
64,
171
],
[
171,
25,
951
]
],
[
[
1446,
23,
907
],
[
907,
63,
1476
],
[
1476,
63,
951
]
],
[
[
1446,
24,
159
],
[
159,
62,
907
],
[
907,
62,
951
]
],
[
[
1446,
24,
405
],
[
405,
63,
318
],
[
318,
23,
951
]
]
] | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lanreotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Lanreotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
],
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Lanreotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
]
] | Lanreotide may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Palbociclib
Lanreotide may lead to a major life threatening interaction when taken with Lonafarnib and Lonafarnib may lead to a major life threatening interaction when taken with Palbociclib
Lanreotide may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib |
DB00802 | DB01183 | 1,322 | 173 | [
"DDInter43",
"DDInter1262"
] | Alfentanil | Naloxone | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, causing the rapid removal of any other drugs bound to these receptors. When taken in large quantities, opioid medications such as [morphine], [hydromorphone], [methadone], [heroin], or [fentanyl] are capable of causing life-threatening symptoms such as respiratory depression, reduced heart rate, slurred speech, drowsiness, and constricted pupils.[A234594,L33724] If untreated, this can progress to vomiting, absent pulse and breathing, loss of consciousness, and even death. Naloxone is indicated for the rapid reversal of these symptoms of central nervous system depression in opioid overdose. It's important to note that naloxone only works on opioid receptors within the body, and is therefore not capable of reversing the effects of non-opioid medications such as stimulants like [methamphetamine] or [cocaine], or benzodiazepines like [lorazepam] or [diazepam]. Also known as the brand name product Narcan, naloxone is currently available by intramuscular (IM) or subcutaneous (SubQ) injection, nasal spray, or intravenous (IV) infusion.[L33729,L33739] Naloxone IM injections are commonly available in the form of "kits", which is ideal for making overdose treatment accessible and readily available for administration by minimally trained individuals within the community. Kits commonly include the supplies necessary to treat an overdose in a non-medical setting such as alcohol swabs, syringes, a rescue breathing mask, and instructions for use. Frequently also carried by medical and emergency personnel and at events known to be associated with heavy drug use like music festivals, naloxone kits are considered a key component of harm reduction strategies. There are over-the-counter nasal sprays available. When injected intramuscularly (IM), naloxone acts within three to five minutes. Administration of naloxone is associated with very few side effects. Notably, if injected into a person not currently using opioid medications, there would be no noticeable effects at all. However, for individuals using opioid medications or experiencing an overdose, IM injection of naloxone rapidly reverses opioid effects and can cause the injected individual to immediately experience withdrawal symptoms. Common symptoms of opioid withdrawal include nausea, vomiting, sweating, runny nose, aches, and diarrhea. Although certainly physically uncomfortable, opioid withdrawal symptoms are not life-threatening; administration of naloxone is, therefore, appropriate for any person appearing to have any symptoms of an opioid overdose. Due to its short duration of action, persons injected with naloxone should be monitored for responsiveness and potentially injected a second time or taken to the hospital. Naloxone is also available within the combination product Suboxone with the opioid medication [buprenorphine].[L33714,L33719] Suboxone is used for the maintenance treatment of opioid dependence and addiction.[L33714,L33719] When taken orally, naloxone has no pharmacological effect and does not reduce the effectiveness of the opioid effect of buprenorphine.[L33714,L33719] The primary purpose of including naloxone within Suboxone is to act as a deterrent to injection, as injected naloxone would rapidly reverse the effects of buprenorphine.[L33714,L33719] Naloxone was granted FDA approval on 13 April 1971. | Moderate | 1 | [
[
[
1322,
24,
173
]
],
[
[
1322,
63,
475
],
[
475,
24,
173
]
],
[
[
1322,
64,
267
],
[
267,
40,
173
]
],
[
[
1322,
6,
4973
],
[
4973,
45,
173
]
],
[
[
1322,
21,
28882
],
[
28882,
60,
173
]
],
[
[
1322,
64,
121
],
[
121,
23,
173
]
],
[
[
1322,
40,
411
],
[
411,
24,
173
]
],
[
[
1322,
24,
407
],
[
407,
63,
173
]
],
[
[
1322,
63,
475
],
[
475,
25,
314
],
[
314,
24,
173
]
],
[
[
1322,
64,
267
],
[
267,
36,
314
],
[
314,
24,
173
]
]
] | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} (Compound) resembles {v} (Compound)",
"Naloxone"
]
],
[
[
"Alfentanil",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Naloxone"
]
],
[
[
"Alfentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Naloxone"
]
],
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxone"
]
],
[
[
"Alfentanil",
"{u} (Compound) resembles {v} (Compound)",
"Remifentanil"
],
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
]
] | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Alfentanil may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone (Compound) resembles Naloxone (Compound)
Alfentanil (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Naloxone (Compound)
Alfentanil (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Naloxone (Compound)
Alfentanil may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Naloxone
Alfentanil (Compound) resembles Remifentanil (Compound) and Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Alfentanil may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone (Compound) resembles Nalbuphine (Compound) and Naltrexone may lead to a major life threatening interaction when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone |
DB00601 | DB00907 | 453 | 290 | [
"DDInter1073",
"DDInter427"
] | Linezolid | Cocaine (topical) | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor. | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Major | 2 | [
[
[
453,
25,
290
]
],
[
[
453,
21,
28658
],
[
28658,
60,
290
]
],
[
[
453,
24,
1637
],
[
1637,
63,
290
]
],
[
[
453,
24,
455
],
[
455,
64,
290
]
],
[
[
453,
64,
1048
],
[
1048,
25,
290
]
],
[
[
453,
24,
1674
],
[
1674,
25,
290
]
],
[
[
453,
25,
1629
],
[
1629,
64,
290
]
],
[
[
453,
25,
247
],
[
247,
76,
290
]
],
[
[
453,
21,
28658
],
[
28658,
60,
85
],
[
85,
1,
290
]
],
[
[
453,
24,
1637
],
[
1637,
63,
697
],
[
697,
63,
290
]
]
] | [
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Linezolid",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cocaine"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cocaine"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxapram"
],
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Linezolid",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atropine"
],
[
"Atropine",
"{u} (Compound) resembles {v} (Compound)",
"Cocaine"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cocaine"
]
]
] | Linezolid may lead to a major life threatening interaction when taken with Cocaine
Linezolid (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Cocaine (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Cocaine
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Cocaine
Linezolid may lead to a major life threatening interaction when taken with Doxapram and Doxapram may lead to a major life threatening interaction when taken with Cocaine
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may lead to a major life threatening interaction when taken with Cocaine
Linezolid may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Cocaine
Linezolid may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Cocaine and Iobenguane may lead to a major life threatening interaction when taken with Cocaine
Linezolid (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Atropine (Compound) and Atropine (Compound) resembles Cocaine (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cocaine |
DB00196 | DB00222 | 600 | 245 | [
"DDInter743",
"DDInter825"
] | Fluconazole | Glimepiride | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels (K<SUB>ATP</SUB> channels) and causing depolarization of the beta cells. Compared to [glipizide], another second SU drug, glimepiride has a longer duration of action. It is sometimes classified as a third-generation SU because it has larger substitutions than other second-generation SUs. Compared to other SUs, glimepiride was associated with a lower risk of developing hypoglycemia and weight gain in clinical trials as well as fewer cardiovascular effects than other SUs due to minimal effects on ischemic preconditioning of cardiac myocytes. It is effective in reducing fasting plasma glucose, postprandial glucose, and glycosylated hemoglobin levels and is considered to be a useful, cost-effective treatment option for managing type 2 diabetes mellitus. Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM. It is commonly marketed under the brand name Amaryl as oral tablets and is typically administered once daily. | Major | 2 | [
[
[
600,
25,
245
]
],
[
[
600,
25,
959
],
[
959,
1,
245
]
],
[
[
600,
6,
6017
],
[
6017,
45,
245
]
],
[
[
600,
21,
29024
],
[
29024,
60,
245
]
],
[
[
600,
25,
1347
],
[
1347,
62,
245
]
],
[
[
600,
24,
660
],
[
660,
62,
245
]
],
[
[
600,
25,
1487
],
[
1487,
63,
245
]
],
[
[
600,
24,
655
],
[
655,
63,
245
]
],
[
[
600,
63,
521
],
[
521,
24,
245
]
],
[
[
600,
24,
798
],
[
798,
24,
245
]
]
] | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glimepiride"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Glimepiride"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Glimepiride"
]
],
[
[
"Fluconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Glimepiride"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
]
]
] | Fluconazole may lead to a major life threatening interaction when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound)
Fluconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glimepiride (Compound)
Fluconazole (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Glimepiride (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Glimepiride
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glimepiride
Fluconazole may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride |
DB00387 | DB06691 | 1,386 | 849 | [
"DDInter1528",
"DDInter1155"
] | Procyclidine | Mepyramine | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
1386,
24,
849
]
],
[
[
1386,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1386,
24,
272
],
[
272,
24,
849
]
],
[
[
1386,
24,
1116
],
[
1116,
63,
849
]
],
[
[
1386,
40,
456
],
[
456,
24,
849
]
],
[
[
1386,
35,
1192
],
[
1192,
24,
849
]
],
[
[
1386,
25,
1621
],
[
1621,
25,
849
]
],
[
[
1386,
24,
662
],
[
662,
35,
849
]
],
[
[
1386,
63,
1594
],
[
1594,
1,
11775
],
[
11775,
40,
849
]
],
[
[
1386,
24,
272
],
[
272,
1,
11775
],
[
11775,
40,
849
]
]
] | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
],
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound)",
"Biperiden"
],
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Procyclidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepyramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
]
] | Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium and Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Procyclidine (Compound) resembles Biperiden (Compound) and Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Procyclidine (Compound) resembles Glycopyrronium (Compound) and Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Procyclidine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Mepyramine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound)
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound) |
DB00023 | DB00754 | 305 | 157 | [
"DDInter127",
"DDInter696"
] | Asparaginase Escherichia coli | Ethotoin | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used. | Moderate | 1 | [
[
[
305,
24,
157
]
],
[
[
305,
24,
167
],
[
167,
24,
157
]
],
[
[
305,
24,
384
],
[
384,
63,
157
]
],
[
[
305,
25,
770
],
[
770,
63,
157
]
],
[
[
305,
25,
1064
],
[
1064,
25,
157
]
],
[
[
305,
25,
1510
],
[
1510,
64,
157
]
],
[
[
305,
24,
600
],
[
600,
25,
157
]
],
[
[
305,
24,
167
],
[
167,
24,
759
],
[
759,
40,
157
]
],
[
[
305,
24,
663
],
[
663,
18,
7248
],
[
7248,
46,
157
]
],
[
[
305,
24,
482
],
[
482,
21,
28658
],
[
28658,
60,
157
]
]
] | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ethotoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ethotoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ethotoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Ethotoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"RPP38"
],
[
"RPP38",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethotoin"
]
]
] | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Ethotoin
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ethotoin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ethotoin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) downregulates RPP38 (Gene) and RPP38 (Gene) is upregulated by Ethotoin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Ethotoin (Compound) |
DB00782 | DB06691 | 1,123 | 849 | [
"DDInter1535",
"DDInter1155"
] | Propantheline | Mepyramine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
1123,
24,
849
]
],
[
[
1123,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1123,
24,
272
],
[
272,
24,
849
]
],
[
[
1123,
24,
1116
],
[
1116,
63,
849
]
],
[
[
1123,
62,
1014
],
[
1014,
24,
849
]
],
[
[
1123,
23,
1605
],
[
1605,
24,
849
]
],
[
[
1123,
63,
675
],
[
675,
25,
849
]
],
[
[
1123,
64,
1621
],
[
1621,
25,
849
]
],
[
[
1123,
25,
306
],
[
306,
25,
849
]
],
[
[
1123,
24,
1301
],
[
1301,
25,
849
]
]
] | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
],
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Propantheline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Propantheline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepyramine"
]
],
[
[
"Propantheline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepyramine"
]
],
[
[
"Propantheline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
],
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepyramine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepyramine"
]
]
] | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium and Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Propantheline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Propantheline may cause a minor interaction that can limit clinical effects when taken with Indapamide and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Mepyramine
Propantheline may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Mepyramine
Propantheline may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may lead to a major life threatening interaction when taken with Mepyramine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol and Levacetylmethadol may lead to a major life threatening interaction when taken with Mepyramine |
DB00092 | DB12893 | 58 | 586 | [
"DDInter40",
"DDInter1629"
] | Alefacept | Sacituzumab govitecan | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38.[L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated approval for the treatment of mTNBC patients who have undergone two or more prior therapies. As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects. In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] | Moderate | 1 | [
[
[
58,
24,
586
]
],
[
[
58,
24,
270
],
[
270,
24,
586
]
],
[
[
58,
63,
1184
],
[
1184,
24,
586
]
],
[
[
58,
25,
1377
],
[
1377,
25,
586
]
],
[
[
58,
24,
1619
],
[
1619,
25,
586
]
],
[
[
58,
63,
1057
],
[
1057,
25,
586
]
],
[
[
58,
24,
270
],
[
270,
63,
713
],
[
713,
24,
586
]
],
[
[
58,
24,
713
],
[
713,
24,
270
],
[
270,
24,
586
]
],
[
[
58,
63,
1184
],
[
1184,
24,
270
],
[
270,
24,
586
]
],
[
[
58,
25,
1377
],
[
1377,
25,
270
],
[
270,
24,
586
]
]
] | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
]
] | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Alefacept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Sacituzumab govitecan
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Sacituzumab govitecan
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Sacituzumab govitecan
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Alefacept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan |
DB00008 | DB08913 | 491 | 1,186 | [
"DDInter1407",
"DDInter1561"
] | Peginterferon alfa-2a | Radium Ra 223 dichloride | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm. | Moderate | 1 | [
[
[
491,
24,
1186
]
],
[
[
491,
24,
134
],
[
134,
24,
1186
]
],
[
[
491,
23,
450
],
[
450,
24,
1186
]
],
[
[
491,
24,
1362
],
[
1362,
63,
1186
]
],
[
[
491,
25,
1377
],
[
1377,
24,
1186
]
],
[
[
491,
25,
1259
],
[
1259,
63,
1186
]
],
[
[
491,
24,
134
],
[
134,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
491,
23,
450
],
[
450,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
491,
24,
1362
],
[
1362,
63,
37
],
[
37,
24,
1186
]
],
[
[
491,
24,
599
],
[
599,
24,
37
],
[
37,
24,
1186
]
]
] | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Radium Ra 223 dichloride"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Radium Ra 223 dichloride"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
]
] | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride |
DB01118 | DB01177 | 33 | 77 | [
"DDInter76",
"DDInter904"
] | Amiodarone | Idarubicin | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286] | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
33,
25,
77
]
],
[
[
33,
6,
6017
],
[
6017,
45,
77
]
],
[
[
33,
7,
2703
],
[
2703,
46,
77
]
],
[
[
33,
18,
4410
],
[
4410,
57,
77
]
],
[
[
33,
7,
5998
],
[
5998,
57,
77
]
],
[
[
33,
21,
29170
],
[
29170,
60,
77
]
],
[
[
33,
63,
112
],
[
112,
23,
77
]
],
[
[
33,
25,
823
],
[
823,
63,
77
]
],
[
[
33,
64,
543
],
[
543,
24,
77
]
],
[
[
33,
25,
918
],
[
918,
24,
77
]
]
] | [
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Amiodarone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Amiodarone",
"{u} (Compound) upregulates {v} (Gene)",
"IKZF1"
],
[
"IKZF1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Amiodarone",
"{u} (Compound) downregulates {v} (Gene)",
"VAPB"
],
[
"VAPB",
"{u} (Gene) is downregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Amiodarone",
"{u} (Compound) upregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Amiodarone",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure congestive"
],
[
"Cardiac failure congestive",
"{u} (Side Effect) is caused by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
]
] | Amiodarone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Amiodarone (Compound) upregulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Idarubicin (Compound)
Amiodarone (Compound) downregulates VAPB (Gene) and VAPB (Gene) is downregulated by Idarubicin (Compound)
Amiodarone (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Idarubicin (Compound)
Amiodarone (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Idarubicin (Compound)
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Amiodarone may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Amiodarone may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Amiodarone may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin |
DB00431 | DB00831 | 1,503 | 1,178 | [
"DDInter1072",
"DDInter1866"
] | Lindane | Trifluoperazine | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical treatment of pediculosis capitis (head lice), pediculosis pubis (pubic lice), or scabies in patients greater than two years of age who cannot tolerate or have failed first-line treatment. Lindane is still allowed for pharmaceutical use until 2015. | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
1503,
24,
1178
]
],
[
[
1503,
63,
695
],
[
695,
40,
1178
]
],
[
[
1503,
24,
146
],
[
146,
40,
1178
]
],
[
[
1503,
24,
9
],
[
9,
1,
1178
]
],
[
[
1503,
21,
28751
],
[
28751,
60,
1178
]
],
[
[
1503,
63,
1466
],
[
1466,
24,
1178
]
],
[
[
1503,
24,
913
],
[
913,
63,
1178
]
],
[
[
1503,
24,
530
],
[
530,
24,
1178
]
],
[
[
1503,
25,
497
],
[
497,
64,
1178
]
],
[
[
1503,
63,
475
],
[
475,
25,
1178
]
]
] | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
"Propiomazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Lindane",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Lindane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluoperazine"
]
]
] | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine (Compound) resembles Trifluoperazine (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine (Compound) resembles Trifluoperazine (Compound)
Lindane (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Trifluoperazine (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Lindane may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Trifluoperazine
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Trifluoperazine |
DB00207 | DB00983 | 1,570 | 480 | [
"DDInter157",
"DDInter776"
] | Azithromycin | Formoterol | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting muscarinic antagonists.[L10992,L10989] | Moderate | 1 | [
[
[
1570,
24,
480
]
],
[
[
1570,
24,
1148
],
[
1148,
63,
480
]
],
[
[
1570,
6,
8717
],
[
8717,
45,
480
]
],
[
[
1570,
21,
28963
],
[
28963,
60,
480
]
],
[
[
1570,
25,
868
],
[
868,
63,
480
]
],
[
[
1570,
24,
1424
],
[
1424,
24,
480
]
],
[
[
1570,
25,
702
],
[
702,
24,
480
]
],
[
[
1570,
63,
618
],
[
618,
24,
480
]
],
[
[
1570,
40,
1056
],
[
1056,
24,
480
]
],
[
[
1570,
25,
877
],
[
877,
64,
480
]
]
] | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Azithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)",
"Formoterol"
]
],
[
[
"Azithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Formoterol"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Azithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Telithromycin"
],
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Formoterol"
]
]
] | Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Azithromycin (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Formoterol (Compound)
Azithromycin (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Formoterol (Compound)
Azithromycin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Azithromycin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Azithromycin (Compound) resembles Telithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Azithromycin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Formoterol |
DB00279 | DB00390 | 1,152 | 1,252 | [
"DDInter1074",
"DDInter554"
] | Liothyronine | Digoxin | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956. | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s. | Moderate | 1 | [
[
[
1152,
24,
1252
]
],
[
[
1152,
24,
1482
],
[
1482,
40,
1252
]
],
[
[
1152,
6,
16560
],
[
16560,
45,
1252
]
],
[
[
1152,
7,
13230
],
[
13230,
46,
1252
]
],
[
[
1152,
21,
29118
],
[
29118,
60,
1252
]
],
[
[
1152,
24,
1283
],
[
1283,
62,
1252
]
],
[
[
1152,
24,
101
],
[
101,
63,
1252
]
],
[
[
1152,
63,
837
],
[
837,
24,
1252
]
],
[
[
1152,
24,
1636
],
[
1636,
24,
1252
]
],
[
[
1152,
23,
417
],
[
417,
24,
1252
]
]
] | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
]
],
[
[
"Liothyronine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A8"
],
[
"SLC22A8",
"{u} (Gene) is bound by {v} (Compound)",
"Digoxin"
]
],
[
[
"Liothyronine",
"{u} (Compound) upregulates {v} (Gene)",
"TIPARP"
],
[
"TIPARP",
"{u} (Gene) is upregulated by {v} (Compound)",
"Digoxin"
]
],
[
[
"Liothyronine",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Digoxin"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
]
],
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
]
]
] | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin (Compound) resembles Digoxin (Compound)
Liothyronine (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Digoxin (Compound)
Liothyronine (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Digoxin (Compound)
Liothyronine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Digoxin (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Digoxin
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Digoxin
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Digoxin
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin
Liothyronine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Digoxin |
DB00332 | DB00810 | 1,089 | 456 | [
"DDInter970",
"DDInter211"
] | Ipratropium | Biperiden | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891] | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | Moderate | 1 | [
[
[
1089,
24,
456
]
],
[
[
1089,
24,
1105
],
[
1105,
40,
456
]
],
[
[
1089,
6,
4304
],
[
4304,
45,
456
]
],
[
[
1089,
7,
6314
],
[
6314,
46,
456
]
],
[
[
1089,
18,
11048
],
[
11048,
57,
456
]
],
[
[
1089,
24,
104
],
[
104,
63,
456
]
],
[
[
1089,
24,
832
],
[
832,
24,
456
]
],
[
[
1089,
63,
701
],
[
701,
24,
456
]
],
[
[
1089,
35,
19
],
[
19,
24,
456
]
],
[
[
1089,
24,
1105
],
[
1105,
1,
11479
],
[
11479,
40,
456
]
]
] | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound)",
"Biperiden"
]
],
[
[
"Ipratropium",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Biperiden"
]
],
[
[
"Ipratropium",
"{u} (Compound) upregulates {v} (Gene)",
"TLR4"
],
[
"TLR4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Biperiden"
]
],
[
[
"Ipratropium",
"{u} (Compound) downregulates {v} (Gene)",
"VAT1"
],
[
"VAT1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Biperiden"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
]
],
[
[
"Ipratropium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound)",
"Oxyphencyclimine"
],
[
"Oxyphencyclimine",
"{u} (Compound) resembles {v} (Compound)",
"Biperiden"
]
]
] | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Biperiden (Compound)
Ipratropium (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Biperiden (Compound)
Ipratropium (Compound) upregulates TLR4 (Gene) and TLR4 (Gene) is upregulated by Biperiden (Compound)
Ipratropium (Compound) downregulates VAT1 (Gene) and VAT1 (Gene) is downregulated by Biperiden (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Biperiden
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Biperiden
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Biperiden
Ipratropium (Compound) resembles Hyoscyamine (Compound) and Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Biperiden
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Oxyphencyclimine (Compound) and Oxyphencyclimine (Compound) resembles Biperiden (Compound) |
DB08882 | DB11732 | 1,281 | 1,097 | [
"DDInter1070",
"DDInter1027"
] | Linagliptin | Lasmiditan | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011. | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety. Their use is not devoid of concerns, however, and their vasoconstrictive activity can lead to blood pressure lability and other cardiovascular side effects - for this reason, these medications are less suitable for use in patients with pre-existing cardiovascular disorders. Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically implicated in their vasoconstrictive activity.[A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for the adverse effect profile of its predecessors - in other words, lasmiditan’s selectivity allows for the successful termination of migraines without causing vasoconstriction.[A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class of anti-migraine medications in which lasmiditan is the first and only member: the neurally-acting anti-migraine medications (NAAMAs).[A187322,A187307] | Moderate | 1 | [
[
[
1281,
24,
1097
]
],
[
[
1281,
24,
971
],
[
971,
63,
1097
]
],
[
[
1281,
63,
850
],
[
850,
24,
1097
]
],
[
[
1281,
63,
222
],
[
222,
25,
1097
]
],
[
[
1281,
24,
971
],
[
971,
63,
1181
],
[
1181,
24,
1097
]
],
[
[
1281,
63,
850
],
[
850,
24,
971
],
[
971,
63,
1097
]
],
[
[
1281,
63,
999
],
[
999,
63,
701
],
[
701,
24,
1097
]
],
[
[
1281,
63,
868
],
[
868,
64,
1181
],
[
1181,
24,
1097
]
],
[
[
1281,
24,
1033
],
[
1033,
24,
971
],
[
971,
63,
1097
]
],
[
[
1281,
63,
121
],
[
121,
24,
478
],
[
478,
24,
1097
]
]
] | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lasmiditan"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
]
] | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Lasmiditan
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan |
DB00586 | DB00661 | 1,512 | 122 | [
"DDInter537",
"DDInter1928"
] | Diclofenac | Verapamil | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate. | Minor | 0 | [
[
[
1512,
23,
122
]
],
[
[
1512,
10,
11610
],
[
11610,
44,
122
]
],
[
[
1512,
6,
10417
],
[
10417,
45,
122
]
],
[
[
1512,
21,
28809
],
[
28809,
60,
122
]
],
[
[
1512,
24,
222
],
[
222,
62,
122
]
],
[
[
1512,
24,
723
],
[
723,
63,
122
]
],
[
[
1512,
25,
1618
],
[
1618,
63,
122
]
],
[
[
1512,
63,
702
],
[
702,
24,
122
]
],
[
[
1512,
24,
175
],
[
175,
24,
122
]
],
[
[
1512,
62,
752
],
[
752,
24,
122
]
]
] | [
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Verapamil"
]
],
[
[
"Diclofenac",
"{u} (Compound) palliates {v} (Disease)",
"migraine"
],
[
"migraine",
"{u} (Disease) is treated by {v} (Compound)",
"Verapamil"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
"Verapamil"
]
],
[
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Verapamil"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Verapamil"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
]
] | Diclofenac (Compound) palliates migraine (Disease) and migraine (Disease) is treated by Verapamil (Compound)
Diclofenac (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Verapamil (Compound)
Diclofenac (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Verapamil (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Verapamil
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Verapamil
Diclofenac may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Verapamil
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Verapamil
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Verapamil
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Verapamil |
DB00660 | DB00719 | 1,470 | 1,219 | [
"DDInter1163",
"DDInter149"
] | Metaxalone | Azatadine | Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression. Metaxalone is associated with few side effects and is available as a 800 mg scored tablet. | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. | Moderate | 1 | [
[
[
1470,
24,
1219
]
],
[
[
1470,
63,
13
],
[
13,
24,
1219
]
],
[
[
1470,
24,
1376
],
[
1376,
63,
1219
]
],
[
[
1470,
64,
475
],
[
475,
24,
1219
]
],
[
[
1470,
24,
717
],
[
717,
24,
1219
]
],
[
[
1470,
63,
13
],
[
13,
1,
11693
],
[
11693,
40,
1219
]
],
[
[
1470,
63,
530
],
[
530,
63,
13
],
[
13,
24,
1219
]
],
[
[
1470,
24,
1376
],
[
1376,
63,
13
],
[
13,
24,
1219
]
],
[
[
1470,
63,
1242
],
[
1242,
24,
13
],
[
13,
24,
1219
]
],
[
[
1470,
64,
475
],
[
475,
24,
13
],
[
13,
24,
1219
]
]
] | [
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Metaxalone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
],
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound)",
"Ketotifen"
],
[
"Ketotifen",
"{u} (Compound) resembles {v} (Compound)",
"Azatadine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Metaxalone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
]
] | Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Metaxalone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine (Compound) resembles Ketotifen (Compound) and Ketotifen (Compound) resembles Azatadine (Compound)
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Metaxalone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine |
DB00816 | DB01309 | 1,674 | 1,254 | [
"DDInter1346",
"DDInter933"
] | Orciprenaline | Insulin glulisine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as , , and to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy. | Moderate | 1 | [
[
[
1674,
24,
1254
]
],
[
[
1674,
63,
1424
],
[
1424,
24,
1254
]
],
[
[
1674,
62,
167
],
[
167,
24,
1254
]
],
[
[
1674,
24,
280
],
[
280,
63,
1254
]
],
[
[
1674,
23,
1220
],
[
1220,
24,
1254
]
],
[
[
1674,
25,
887
],
[
887,
24,
1254
]
],
[
[
1674,
24,
480
],
[
480,
24,
1254
]
],
[
[
1674,
64,
494
],
[
494,
24,
1254
]
],
[
[
1674,
25,
877
],
[
877,
63,
1254
]
],
[
[
1674,
75,
17
],
[
17,
24,
1254
]
]
] | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
],
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Orciprenaline",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
]
] | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Orciprenaline may lead to a major life threatening interaction when taken with Pindolol and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Orciprenaline may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Orciprenaline may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Orciprenaline (Compound) resembles Sotalol (Compound) and Orciprenaline may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine |
DB00209 | DB00726 | 352 | 1,164 | [
"DDInter1886",
"DDInter1876"
] | Trospium | Trimipramine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007. | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
352,
24,
1164
]
],
[
[
352,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
352,
6,
12523
],
[
12523,
45,
1164
]
],
[
[
352,
21,
29305
],
[
29305,
60,
1164
]
],
[
[
352,
24,
999
],
[
999,
24,
1164
]
],
[
[
352,
24,
830
],
[
830,
63,
1164
]
],
[
[
352,
35,
262
],
[
262,
63,
1164
]
],
[
[
352,
25,
1621
],
[
1621,
64,
1164
]
],
[
[
352,
24,
104
],
[
104,
74,
1164
]
],
[
[
352,
24,
1237
],
[
1237,
1,
11394
],
[
11394,
40,
1164
]
]
] | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
]
],
[
[
"Trospium",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Trimipramine"
]
],
[
[
"Trospium",
"{u} (Compound) causes {v} (Side Effect)",
"Dysgeusia"
],
[
"Dysgeusia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trimipramine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Trospium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Trospium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimipramine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} (Compound) resembles {v} (Compound)",
"Cyamemazine"
],
[
"Cyamemazine",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
]
]
] | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Trospium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Trimipramine (Compound)
Trospium (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Trimipramine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Trospium (Compound) resembles Clidinium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Trospium may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Trimipramine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Trimipramine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Cyamemazine (Compound) and Cyamemazine (Compound) resembles Trimipramine (Compound) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.